CA1334845C - 16,17-acetalsubstituted androstane-17.beta.-carboxylic acid esters - Google Patents
16,17-acetalsubstituted androstane-17.beta.-carboxylic acid estersInfo
- Publication number
- CA1334845C CA1334845C CA000589467A CA589467A CA1334845C CA 1334845 C CA1334845 C CA 1334845C CA 000589467 A CA000589467 A CA 000589467A CA 589467 A CA589467 A CA 589467A CA 1334845 C CA1334845 C CA 1334845C
- Authority
- CA
- Canada
- Prior art keywords
- formula
- hydrogen
- compound
- diene
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Steroid Compounds (AREA)
Abstract
The invention relates to the preparation of a compound of the formula or a stereoisomeric compound thereof, in which formula the 1,2-position is saturated or is a double bond, X1 is selected from hydrogen, fluorine, chlorine and bromine, X2 is selected from hydrogen, fluorine, chlorine and bromine, R2 is selected from straight and branched hydrocarbon chains having 1 to 10 carbon atoms and R7 is hydrogen or an acyl group with 1 to 10 carbon atoms arranged in a straight or branched chain, characterized by reaction of a steroid compound of the formula with an aldehyde compound of the formula
Description
`~ 1334845 Our copending Application Serial No. 505,744 relates to novel, pharmacologically active compounds and a process for their preparation. The invention also relates to pharmaceutical composition containing the compounds and to methods of treatment of inflammatory, allergic, musco-skeletal or dermatological conditions with these compounds. This application is divided out of Application Serial No. 505,744.
The object of the invention of Application Serial No.
505,744 is to provide a glucocorticosteroid which possesses high anti-inflammatory potency at the place of application and low glucocorticoid systemic potency. This divisional Application is concerned with a process for preparing certain compounds useful as intermediates in the preparation of the glucocorticosteroids of Application Serial No. 5~5,744.
Backqround Art It is known that certain glucocorticosteroids (GCS) can be used for local therapy of inflammatory, allergic or immuno-logic diseases in respiratory airways (e.g. asthma, rhinitis), in skin (eczema, psoriasis) or in bowel (ulcerative colitis, Morbus Crohn). With such local glucocorticoid therapy, clinical advan-tages over general therapy (with e.g. glucocorticoid tablets) are obtained, especially regarding reduction of the unwanted glucocorticoid effects outside the diseased area. To reach such clinical advantages, in e.g. severe respiratory airway disease, GCS must have a suitable pharmacological profile. They should have high intrinsic glucocorticoid activity at the application site ~' - 1~34845 but also a rapid inactivation by e.g. hydrolysis in the target organ or after uptake into the general circulation.
Since binding of GCS to the glucocorticoid receptor is a pre-requisite for their anti-inflammatory and allergic effects to occur, the ability of steroids to bind to their receptor(s) can be used as an adequate method for determining the biological activity of GCS. A direct correlation between the affinity of GCSs to the receptor and their anti-inflammatory effects has been shown using ear edema test in the rat. [Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 ~,17~ -acetal substituted gluco-corticoids. E. Dahlberg, A. Thalén, R. Brattsand, J-A Gustafsson, U. Johansson, K. Roempke, and T. Saartok, Mol. Pharmacol. 25 (1984), 70.]
Disclosure of the Invention ___________________________ The invention of Application Serial No. 505,744 is based on the observation that certain 3-oxo-androsta-1,4-diene-17~-carboxylic acid esters possess high binding affinity to the glucocorticosteroid receptor. The compounds can be used for the treatment and control of inflammatory conditions.
The compounds of the invention of Application Serial No. 505,744 are characterized by the formula - 2a - - 23940-529D
OlR3 C=O
H0 ~ = 0 ~ CRlR2 I
0~
wherein the 1,2-position is saturated or is a double bond Xl is selected from hydrogen, fluorine, chlorine and bromine X2 is selected from hydrogen, fluorine, chlorine and bromine Rl is selected from hydrogen or a straight or branched hydrocarbon chain having 1-4 carbon atoms R2 is selected from hydrogen or straight and branched hydrocarbon chains having 1-10 carbon atoms and O O
.. ..
R3 is selected from CR4R50C~6 or CR4R50 6 Y is 0 or S
R4 is selected from hydrogen, straight or branched hydrocarbon chains having 1-10 carbon atoms or from phenyl R5 is selected from hydrogen or methyl and R6 is selected from hydrogen, straight or branched, saturated or unsatur-ated hydrocarbon chains having 1-10 carbon atoms, an alkyl group substituted by at least one halogen atom, a heterocyclic ring system containing 3-10 atoms in the ring system, -(CH2)m CH(CH2)n (m =
_ 5 0,1,2; n = 2,3,4,5,6), phenyl or benzyl groups which are unsubstitut-ed or substituted by one or more alkyl, nitro, carboxy, alkoxy, halo-gen, cyano, carbalkoxy or trifluoromethyl group(s), provided that when R2 is hydrogen Rl is methyl.
The individual stereoisomeric components present in a mixture of a stero-id having the above formula (I) can be elucidated in the following way:
H0 ~ _ 0, C~
CH3 I Rl (II; epimer S) CH C = 0 R
H0 ~ _ ~ C~
~, ~ (III; epimer R) The individual stereoisomeric components present, in a mixture of stero-id 17~-carboxylic acid esters having the formulas StCOCR4R50CR6 (IV) or O O
Il 11 StCOCR4R50CYR6 -(V) '. -1334845 where St is the steroid moiety, can be elucidated in the following way 8 ~4e 8 R4,01 StCOC,OCR6 StCOCOCR6 VI VII
and StCOCOCYR6 1l ~41l VIII IX
In diasteroisomers like II, III, VI, VII, VIII and IX, the configuration differs only at one out of several asymmetric carbon atoms. Such dia-stereoisomers are denoted epimers, Alkyl in thedefinitions above is a straight or branched hydrocarbon chain with 1-5 carbon atoms, preferably l-4 C.
Alkoxy in the definition above is a group -0-alkyl wherein the alkyl moiety has the above given definition.
Halogen in the definition above is preferably a chlorine, bromine or fluorine atom.
Carbalkoxy in the definition above is a group -C00-alkyl wherein the alkyl moiety has the above given definition.
Heterocyclic ring system is a ring system containing as hetero atoms N, 0 or S.
Preferred systems are pyrryl, pyrridyl, pyrimidyl, pyrazinyl, furyl, pyranyl, benzofuranyl, indolyl and thienyl.
Particular compounds of the invention which are preferred:
J
l'-Ethoxycarbonyloxyethyl 6~,9~-difluoro-llB-hydroxy-16~,17~-[(1-methyl-ethylidene)bis(oxy)]-androsta-1,4-diene-3-one-17~-carboxylate, the epi-meric mixture A + B and epimer B.
l'-isopropoxycarbonyloxyethyl 9~-fluoro-11~-hydroxy-16~,17~-[(1-methyl-ethylidene)bis(oxy)]-androsta-1,4-diene-3-one-17B-carboxylate, epimer B.
l'-propoxycarbonyloxyethyl 6~,9~-difluoro-11~-hydroxy-16~,17~-[(1--methylethylidene)bistoxy)]androxta-1,4-diene-3-one-17~-carboxylate, epimer B.
l'-isopropoxycarbonyloxyethyl 6~,9~-difluoro-11~-hydroxy-16~,17~-[(1--methylethylidene)bis(oxy)]androsta-1,4-diene-3-one-17~-carboxylate, epimeric mixture A + B and epimer B.
l'-Acetoxyethyl (20R)-9~-fluoro-11~-hydroxy-16~,17~-propylmethylene-dioxyandrosta-1,4-diene-3-one-17~-carboxylate, epimer B.
l'-Ethoxycarbonyloxyethyl (22R)-9~-fluoro-11~-hydroxy-16~,17~-propyl-methylenedioxyandrosta-1,4-diene-3-one-17~-carboxylate, epimer B.
l'-i,opropoxycarbonyloxyethyl ~20R)-9~-fluoro-11~-hydroxy-16~,17~--propylmethylenedioxyandrosta-1,4-diene-3-one-17~-carboxylate, epimer B.
l'-Ethoxycarbonyloxyethyl (20R)-6~,9~-difluoro-11~-hydroxy-16~,17~-propylmethylenedioxyandrosta-1,4-diene-3-one-17B-carboxylate, epimeric mixture A + B and epimer B.
Methods of Preearation _ The compounds of the invention are prepared by the oxidation of a com-pound of the formulas X, XI and XII to the corresponding 17~-carboxylic acid:
fH2-OR7 C=O
HO ~ - - ~ CR R
0~
Xz ~ ```R
XI
0~
C=O ~ R
HO ~ - ~ C~-~R XII
~, 0~
wherein the solid and broken lines between C-l and C-2 represent a single or double bond, ~, 1339~8452394O-529D
Xl, X2, Rl and R2 have the meaning given above, and R7 is hydrogen or an acyl group with 1-10 carbon atoms arranged in a straight or branched chain.
The 17~-carboxylic acids then are esterified to give compounds character-ized by the formula I-IX, wherein --- Xl, X2, Rl, R2 and R3 have the meaning given above.
The process of converting a compound of formulas X, XI
or XII to the corresponding 17-carboxylic acids is carried out in a suitable oxygenated hydrocarbon solvent such as a lower alkanol. Methanol and ethanol are preferred, particularly the former. The reaction medium is made slightly alkaline by the addition of a suitable weak inorganic base such as an alkali metal carbonate, for example sodium, lithium or potassium carbonate. The latter is preferred. The conversion o~ a compound of formula X, XI or XII to a 17~-carboxylic acid of formula I, II or III (R3=H) takes place at ambient temperatures, i.e. 20-25C.
The presence of oxygen is necessary for the reaction. Oxygen can be supplied by bubbling a stream of air or oxygen into the reaction mixture.
The oxidative degradaticn of the 17~ side-chain of compounds of formula X, XI and XII to the correspondi~g 17~ carboxylic acids can also be carried out with periodic acid, sodium h~pobromate or with sodium bis-muthate. The reaction is performed in a mixture of water and a suitable oxygenated hydrocarbon solvent such as a lower ether. Dioxane and tetra-hydrofurane are preferred, particularly the former.
The parent 17~-carboxylic acids of compounds of formula I, II and III
(R3=H) may be esterified in known manner to provide 17~ carboxylate esters according to the invention. For example, the 17~-carboxylic acid may be reacted with an appropriate alcohol and a carbodiimide, e.g.
dicyclohexylcarbodiimide, in a suitable solvent such as diethylether, tetrahydrofurane, methylene chloride or pyridine advantageously at a temperature of 25-100C. Alternatively, a salt of the 17~-carboxylic acid with an alkali metal, e.g. lithium, sodium or potassium, a salt ` - -8 13348~5 of a quaternary ammonium compound, such as a salt of triethyl-or tri-butylamine, or tetrabutylammonium, may be reacted with an appropriate alkylating agent, for example an acyloxyalkylhalide or haloalkyl alkyl-- carbonate preferably in a polar solvent medium such as acetone, methyl-ethylketone or dimethyl formamide, dimethyl sulphoxide, methylenechlo-ride or chloroform, conveniently at a temperature in the range 25-100C.
The reaction may also be performed in the presence of a crown ether.
The crude steroid ester derivatives formed are after isolation purified by chromatography on a suitable material, for instance cross-linked dextran gels of Sephadex~ LH-type with suitable solvents as eluants, e.g. halogenated hydrocarbons, ethers, esters such as ethyl acetate or acetonitrile.
The individual epimers, which are formed at the acetalisation of the 16~,17~-hydroxy groups or at the esterification of the 17B-carboxylic acids, possess practically identical solubility characteristics. Accord-ingly, they have turned out to be impossible to separate and isolate from the epimeric mixture by conventional method for resolution of ste-reoisomers, e.g. fractionated crystallization. In order to obtain theindividual epimers separately the stereoisomeric mixtures according to the formulas I, IV and V above are subjected to column chromatography, thus separating the epimers II, III, VI, VII, VIII and IX in view of different mobility on the stationary phase. The chromatography may be carried out for instance on cross-linked dextran gels of the type Sephadex~ LH, e.g. Sephadex~ LH-20 in combination with a suitable organic solvent as eluting agent. Sephadex~ LH-20, prepared by Pharmacia Fine Chemicals AB, Uppsala, Sweden, is a beadformed hydroxypropylated dextran gel wherein the dextran chains are cross-linked to give a three-dimen-sional polysaccharide network. As eluting agent, halogenated hydrocar-bons e.g. chloroform or a mixture of heptane-chloroform-ethanol in the proportions 0-50:50-100:10-1 has successfully been used, preferably a 20:20:1 mixture.
As starting materials for the compounds of the invention compounds of the formulas X, XI and XII are used. They are prepared by reaction of compounds with the formula 9 13348~5 C=O
H0 ~ -- O0H
~ XIII
0~
wherein the solid and broken lines between C-l and C-2 represent a single or double bond, and Xl, X2 and R7 have the meaning given above, with an aldehyde of the formula / H
=C\R2 wherein R2 has the meaning given above.
The aldehyde is preferably acetaldehyde, propan~l, butanal, isobutanal, pentanal, 3-methylbutanal, 2,2-dimethylpropanal, hexanal, heptanal, octanal, nonanal and dodecanal. The reaction is carried out by adding the steroid to a solution of the aldehyde together with an acid cata-lyst, e.g. perchloric acid, p-toluene sulphonic acid, hydrochloric acid in an ether, preferably dioxane, or halogenated hydrocarbons, prefer-ably methylene chloride or chloroform.
Compounds X, XI and XII are also prepared by transacetalisation of the corresponding 16~,17~-acetonides CIH20R7 H0 ~ ~ - = 8 ~ C 3 ~
0~
. ' - lO - 1334845 23940-529D
wherein the solid and broken lines between Cl and C2 represent a single or double bond and Xl, X2 and R7 have the meaning given above with an aldehyde of the formula H
\ R
wherein R2 has the meaning given above.
This divisional application is concerned with a process for the preparation of a compound of the formula C=O
CH ~ ___O = = R2 ~=~
O
or a stereoisomeric compound thereof, in which formula the 1,2-position is saturated or is a double bond Xl is selected from hydrogen, fluorine, chlorine and bromine X2 is selected from hydrogen, fluorine, chlorine and bromine R2 is selected from straight and branched hydrocarbon chains having 1-10 carbon atoms and R7 is hydrogen or an acyl group with 1-10 carbon atoms arranged in a straight or branched chain, characterized by reaction of a steroid compound of the formula ~ 23940-529D
C=O
H ~ C`--~ O >C C C H 3 o~'~
with an aldehyde compound of the formula / H
O-C/
wherein X1~ g2~ R2~ R7 and have the meanings given above, in the presence of perchloric acid.
The aldehyde is preferably acetaldehyde, propanal, butanal, isobutanal, pentanal, 3-methylbutanal-, 2,2-dimethyl-propanal, hexanal, heptanal, octanal, nonanal and dodecanal. The reaction can be carried out by adding the steroid to a solution of the aldehyde together with a strong inorganic acid as catalyst, preferably perchloric or hydrochloric acid, in an ether, prefer-ably dioxane or tetrahydrofuran, a halogenated hydrocarbon, preferably methylene chloride or chloroform, an aromatic hydrocarbon, preferably toluene, an alicyclic hydrocarbon, preferably cyclohexane or an aliphatic hydrocarbon, preferably heptane or isooctane, under the latter conditions eliminating the chromatographic step for preparation of the epimers III and XII.
lOa ~~ 23940-529D
Pressurized aerosols for steroids are intended for oral or nasal inhalation. The aerosol system is designed in such a way that each delivered dose contains 10-1000 ~g, preferably 20-250 ~g of the active steroid. The most active steroids are administered lOb 'C
133~845 in the lower part of the dose range. The micronized steroid con-sists of particles substantially smaller than 5 ~m, which are suspended in a propellent mixture with the assistance of a dispersant, such as sorbitan trioleate, oleic acid, lecithin or sodium salt of dioctylsulphosuccinic acid.
Working Examples _ _ _ _ _ _ _ _ _ _ _ _ _ _ The invention of Application Serial No. 505,744 and of this divisional application will be further illustrated by the following non-limitative examples. In the examples a flow-rate of 2.5 ml/cm2-h 1 is used at the preparative chromatographic runs.
Molecular weights are in all examples determined with electron im-pact mass spectrometry and the melting points on a Leitz Wetzlar hot stage microscope. All HPLC analyses (HPLC = High Performance Liquid Chromatography) were performed on a Waters ~Bondapak C18 column (300x3.9 mm internal diameter) with a flow-rate of 1.0 ml/
min and with ethanol-water in ratios between 50:50 and 60:40 as mobile phase, if not otherwise stated.
Example 1. This example sets forth a process for preparing (22~S)-, (22R)- and (22S)-11~,16~,17~,21- tetrahydroxypregna-1,4-diene-3,20-dione 16~,17~-acetals.
Preparation of (22RS)-, (22R)- and (22S)-16~,17~-butylidenedioxy-6~,9~-difluoro-11~,21-dihydroxypregna-1,4-diene-3,20-dione.
A. To a suspension of 1.0 g of 6~,9~-difluoro-11~,16~, 17~,21-tetrahydroxypregna-1-4-diene-3,20-dione in 500 ml of methylene chloride 0.32 ml of freshly distilled n-butanal and 2 ml - lla - 1334845 23940-529D
72% perchloric acid were added. The reaction mixture was allowed to stand for 24 h at room temperature under stirring. The reaction mixture was washed with 10% aqueous potassium carbonate solution and water, dried over sodium sulphate and evaporated.
The residue was dissolved in ethyl acetate and precipitated with petroleum ether leaving 883 mg of (22RS)-16~,17~-butylidenedioxy-6~,9~-difluoro-11~,21-dihydroxypregna-1,4-diene-3,20-dione.
HPLC-analysis showed 99% purity and the ratio 16:84 between the 22S- and 22R-epimers. Molecular weight: 466 (calculated 466.5).
` - -13348~5 The (22RS) epimeric mixture was chromatographed on Sephadex LH-20 column (76 x 6.3 cm) using heptane:chloroform:ethanol, 20:20:1, as mobile phase. The fractions 12315-13425 ml (A) and 13740-15690 ml (B) were collected and evaporated and the residue dissolved in methylene chloride and precipitated with petr.-ether. Fraction A gave 62 mg of (22S)- and fraction B
687 mg of (22R)-16a,17a-butylidenedioxy-6a,9a-difluoro-11~, 21-dihydroxypregna-1,4-diene-3,20-dione. The (22S)-epimer:
Molecular weight 466 (calculated 466.5), m.p. 196-200C.
The (22R)-epimer: Molecular weight 466 (calculated 466.5), m.p. 169-72C.
B. To a solution of 1.0 g of 6a,9a-difluoro-11~, 21-dihydroxy-16a,17a-[(1-methylethylidene)bis(oxy)] pregna-1,4-diene-3,20-dione in 500 ml of methylene chloride was added 0.30 ml freshly distilled n-butanal and 2 ml of 72% perchloric acid. The reaction mixture was allowed to stand for 24 h at 33C under stirring, extracted with aqueous potassium carbonate and water, dried over sodium su~phate and evaporated. The res-idue was dissolved in methylene chloride and precipitated with petr.-ether yielding 848 mg of (22RS)-16a,17a-bUtylidenedioxy-6a,9a-difluoro-11~,21-dihydroxypregna-1,4-diene-3,20-dione HPLC-analysis showed 93% purity and the ratio 12/88 between the 22S- and 22R-epimers.
B'. To a suspension of 4.0 g of 6a,9a-difluoro-llB,21-dihydroxy-16a,17a-[(methylethylidene)bis(oxy)] pregna-1,4-diene-3,20-dione in 100 ml of heptane was added 1.2 ml of freshly distilled _-butanal and 3.8 ml of perchloric acid (72%).
~ ` 133~8~S
- 12a -The reaction mixture was allowed to stand for 5 h at room temperature under vigorous stirring, extracted with aqueous potassium carbonate and water, dried over sodium sulphate and evaporated yielding 4.0 g of (22Rs)-l6a~l7a-butylidenedi 6a~9a-difluoro-ll R, 21-dihydroxypregna-1,4-diene-3,20-dione.
HPLC-analysis showed 98.5% purity and the ratio 3/97 between the 22S- and 22R-epimers. After two recrystallisations from chloroform-petroleum ether 3,1 g of 22R-epimer was obtained, which contained only 1.1% of the 22S-epimer and 1.3% of other impurities.
C. Similarly, by following the procedure set forth in the example by substituting 6a~9a-difluoro-~ l6a~l7a~2 tetrahydroxypregna-1,4-diene-3,20-dione for llR,16a,17a,21-tetrahydroxypregna-1,4-diene-3,20-dione,9a-fluoro- and 6a-fluoro-ll R ,16a~l7a~2l-tetrahydroxypregna-l~4-diene-3~2o-dione or the corresponding 16a~l7a-acetonides non-fluorinated and fluorinated non-symmetric (22RS)-, (22R)- and (22s)-llR~l6a~
17a~2l-tetrahydroxypregna-l~4-diene-3~2o-dione 16a,17a-acetals from acetaldehyde, propanal, butanal, isobutanal, pentanal, 3-methylbutanal, 2,2-dimethylpropanal, hexanal, heptanal, oct-anal, nonanal and dodecanal are prepared.
~_ 13 1334~45 Example 2 A. Prednacinolon 16~,17a-acetonide (250 mg;0,6 mmol) was dissolved in 75 ml of CH2C12. n-Butanal (130 mg; 1,8 mmol and 70% perchloric acid (0,025ml) were added. The solution was stirred at 33C for 15 hours.
The yellow solution was washed with 2xlO ml of 10% K2C03 and 4xlO ml of H20, dried and evaporated. Yield: 257 mg (97,7%~. HPLC gave 91,1%
purity. Unreacted acetonide consists of 7,4% of the impurities. Epimer ratio 14,6/85,4.
B. Triamcinolon 16O~17~-acetonide (0,5 9; 1,1 mmol) was dissolved in 150 ml of CH2C12. n-Butanal (260 mg; 3,6 mmol) and 70% perchloric acid (0,22 - ml) were added. The mixture way stirred at 33C for 16 hours. CH2C12 was taken over into a separation funnel and the reaction flask was washed several times with 10 ml K2C03 and CH2C12, respectively. The solution was then washed with 2xlO ml of 10% K2C03 and 4xlO ml of H20, dried and evaporated. Yield: 438 mg (84,9%). HPLC gave 80,2% purity. Epimer ratio 19/81.
C. Fluocinolon 16~,17~-acetonide (0,5 9; 1,1 mmol) was dissolved in 150 ml of CH2C12. n-Butanal (260 mg; 3,6 mmol) and 70% perchloric acid (0,22 ml)were added. The mixture was stirred at 33C for 24 hours. The CH2C12 phase was taken over into a separation funnel. The reaction flask was washed several times with 15 ml of 10% K2C03 and CH2C12, respectively.
The solution was washed with 2x15 ml of 10% K2C03 and 4x15 ml of H20, dried and evaporated. Yield: 513 mg (100%). HPLC gave 97,4% purity.
Epimeric ratio 8.6/91,4.
Example 3. This example sets forth a process for preparing ll~-hydroxy-16~,17~- [(l-methylethylidene)bis(oxy)] - and (20RS)-, (20R)- and (20S)-ll~-hydroxy-16~,17a-alkylmethylenedioxyandrosta-1,4-diene-3-one-17~-car-boxylic and -4-ene-3-one-17~-carboxylic acids.
_ . 1334845 Preparation of 6~,9~-difluoro-llB-hydroxy-16~,17~-[(1-methylethylidene)-bis(oxy)]androsta-1,4-diene-3-one-17B-carboxylic acid.
A. To a solution of 1.99-9 of fluocinolone 16~,17~-acetonide in 120 ml of methanol 40 ml of 20% aqueous potassium carbonate was added. A stream of air was bubbled through this solution for about 20 h under stirring at room temperature. The methanol was evaporated and 200 ml of water was added to the residue. The solution was extracted with methylene chloride. The aqueous phase was acidified with diluted hydrochloric acid. The precipitate formed was collected by filtration and dried to yield 1.34 9 of 6~,9~-difluoro-llB-hydroxy-16~,17~-[(1-methylethylidene)-bis(oxy)]androsta-1,4-diene-3-one-17B-carboxylic acid, melting point 264-68C, molecular weight 438. The purity determined by HPLC was 94.0%.
The aqueous phase was extracted with ethyl acetate. After drying the solvent was evaporated leaving another 0.26 9 portion of acid.
Purity: 93.7%.
B. Periodic acid (15.1 9) in 16.5 ml of water was added to a solution of fluocinolone 16~,17~-acetonide (5.0 9) in 55 ml dioxane. The reaction mixture was stirred at room temperature for 20 h, neutralized with satur-ated aqueous sodium hydrogen carbonate and evaporated. The residue was dissolved in 200 ml of methylene chloride and washed with 8 x 100 ml 10% aqueous potassium carbonate. The aqueous phase was acidified with conc. hydrochloric acid and extracted with 6 x 100 ml of ethyl acetate.
After drying the solvent was evaporated. The residue was dissolved in 400 ml of ethyl acetate and precipitated with petroleum ether yielding 3.96 9 of 6~,9~-difluoro-11~-hydroxy-16~,17~-[(1-methylethylidene)bis-(oxy)]androsta-1,4-diene-3-one-17B-carboxylic acid. The purity deter-mined by HPLC was 99.5%.
C. Similarly, by following the procedure set forth in the example by substituting fluocinolone 16~,17~-acetonide for llB,16~,17~,21-tetra-hydroxypregna-1,4-diene-3,20-dione, 6~-fluoro-11~,16,17~,21-tetrahyd-roxypregna-1,4-diene-3,20-dione, and triamcinolone 16~,17~-acetonide llB-hydroxy-16~,17~-[(1-methylethylidene)bis(oxy)]androsta-1,4-diene-- 3-one-17~-carboxylic acids are prepared. By substituting the 16~,17~-acetonide group for 16~,17~-acetals between 16a-hydroxyprednisolone 6~-fluor-16~-hydroxyprednisolone, triamcinolone and fluocinolone and ~J
`- 13348~5 acetaldehyde, propanal, butanal, isobutanal, pentanal, 3-methylbutanal, 2,2-dimethylpropanal, hexanal, heptanal, octanal, nonanal and dodecanal and their 21-esters (20RS)- (20R)- and (20S)-llB-hydroxy-16~,17~-alkyl-methylenedioxyandrosta-1,4-diene- and 4-ene-3-one-17~-carboxylic acids are prepared.
Example 4. l'-Ethoxycarbonyloxyethyl 6~,9~-difluoro-11~-hydroxy-16~,17~-[(l-methylethylidene~bis(oxy)]androsta-1,4-diene-3-one-17~-carboxylate.
A. 6~,9~-Difluoro-ll~-hydroxy-16~,17~-[(1-methylethylidene)bis(oxy)]-androsta-1,4-diene-3-one-17~-carboxylic acid (600 mg) and potassium hydrogen carbonate (684 mg) were dissolved in 45 ml of dimethyl form-amide. 1-Bromoethyl ethyl carbonate (2 ml) was added and the reaction mixture stirred at room temperature overnight. Water (200 ml) was added and the mixture was extracted with methylene chloride. The combined extracts were washed with 5% aqueous sodium hydrogen carbonate and water, and the residue purified by chromatography on a Sephadex LH-20 column (72x6.3 cm) using chloroform as mobil phase. The fraction 1515-2250 ml was collected and evaporated yielding 480 mg of l'-ethoxycarbonyloxy-ethyl 6~,9~-difluoro-11~-hydroxy-16~,17~-[(1-methylethylidene)bis~oxy)]-androsta-1,4-dienc-3-one-17B-carboxylate. The purity determined by HPLC
was 98.1% and the ratio epimer A/B, 48/52. Melting point: 218-27C.
[~]2D5 = +63.2 (c=0.214; CH2C12). The molecular weight was 554.
The l'-ethoxycarbonyloxyethyl 6~,9~-difluoro-11~-hydroxy-16~,17~-(1-methylethylidene)bis(oxy)]androsta-1,4-diene-3-one-17~-carboxylate (480 mg) was chromatographed on a Sephadex LH-20 column (76x6.3 cm) using heptane:chloroform:ethanol, 20 20:1, as mobile phase. The fraction 2325-2715 ml was collected, evaporated and the residue dissolved in methylene chloride and precipitated by petroleum ether giving 200 mg of a compound (A) of purity 97.3% (determined by HPLC analysis). Melting point: 246-50C. [~]2D5 = +100.5 (c=0.214; CH2C12). The molecular weight was 554.
The fraction 4140-5100 ml yielded 250 mg of a compound (B) with purity 99.0%. Melting point: 250-55C. [~]25 = +28.5 (c=0.246; CH2C12). The molecular weight was 554. The methine signal from the ester group is shifted 0.13 ppm downfield in lH-NMR spectrum of B compared to A, while the rest of the spectra are nearly identical. The electron impact mass spectra of A and B are identical apart from the intensities of the mass peaks. These spectroscopic differences and similarities indicate that A
and B are epimers due to the chiral centre in the ester group.
B. 6~,9~-Difluoro-ll~-hydroxy-16~,17~- ~(l-methylethylidene)bis(oxy)~
androsta-1,4-diene-3-one-17~-carboxylic acid (200 mg) was dissolved in 25 ml of dimethylformamide. l-Chloroethyl ethyl carbonate (100 mg), potassium hydrogen carbonate (70 mg) and 18-crown-6-ether were added.
The reaction mixture was stirred at 80C for 3 h, cooled, extracted with methylene chloride after addition of 150 ml of water, dried and evaporated. The crude product was purified in the same way as in procedure A leaving 207 mg of l'-ethoxycarbonyloxyethyl 6,9~-difluoro--11~-hydroxy-16c~17~- ~(l-methylethylidene)bis(oxy)~ androsta-l,4-diene--3-one-17B-carboxylate. The purity (HPLC) was 98.4% and the ratio epimer A/B, 54/46.
C. 6~ 9-Difluoro-ll~-hydroxy-16~ 17~- ~l-methylethylidene)bis(oxy)~
androsta-1,4-diene-3-one-17~-carboxylic acid (200 mg) and 1,5-diazabicyclo [5.4.0] und~cene-5 (140 mg) were suspended in 25 ml of benzene and warmed to reflux. A solution of l-bromoethyl ethyl carbonate (175 mg) in 5 ml of benzene was added and the mixture was refluxed for 2 1/2 h. After cooling 50 ml of methylene chloride was added and the solution was washed with water, dried and evaporated. The crude product was purified in the same way as in procedure A, yielding 207 mg of 1'--ethoxycarbonyloxyethyl 6~ 9a-difluoro-llB-hydroxy-16~,17~-~- [(l-methyl-ethylidene)bis(oxy)~ androsta-1,4-diene-3-one-17~-carboxylate. The purity (HPLC) was 96.4% and the ratio epimer A/B, 44/56.
D. To a solution of 6~,9~-difluoro-llB-hydroxy-16~,17~- [(l-methylethyl-idene)bis(oxy)~ androsta-1,4-diene-3-one-17B-carboxylic acid (100 mg) in 25 ml of acetone 175 mg of ~-bromodiethylcarbonate and 45 mg of anhydrous potassium carbonate were added. The mixture was heated for 6 h at reflux. The cooled reaction mixture was poured into 150 ml of water and extracted with methylene chloride. The extract was washed with water, dried over sodium sulphate and evaporated yielding 65 mg of solid _ J
l'-ethoxycarbonyloxyethyl 6~,9a-difluoro-llB-hydroxy-16~ 17~, ~(l-methylethylidene)bis(oxy)~ androsta-1,4-diene-3-one-17B-carboxylate.
The purity determined by HPLC was 97.6% and the ratlo epimer A/B, 49/51.
E. 6~,9~-Difluoro-ll~-hydroxy-16~,17~- ~(l-methylethylidene)bis(oxy)~
androsta-1,4-diene-3-one-17B-carboxylic acid (500 mg) and tetrabutylammonium hydrogen sulphate (577 mg) were added to 3 ml of lM
sodium hydroxide.A solution of 435 mg of l-bromoethyl ethyl carbonate in 50 ml of methylene chloride was added. The mixture was refluxed with stirring overnight. The two layers were separated. The organic layer was washed with 2xlO ml of water, dried and evaporated. The crude product was purified by chromatography on a Sephadex LH-20 column (72x6.3 cm) using chloroform as mobile phase. The fraction 1545-1950 ml was collected and evaporated and the residue precipitated from methylene chloride - petroleum ether leaving 341 mg of l'-ethoxycarbonyl-oxyethyl 6~,9~-difluoro-llB-hydroxy-16~,17d- ¦(l-methylethylidene)--bis(oxy)~ androsta-1,4-diene-3-one-17B-carboxylate. The purity determined with HPLC was 99.2% and the ratio epimer A/B, 56/44.
F. 6~,9~-Difluoro-llB-hydroxy-16~,17- ~(l-methylethylidene)bis--(oxy)~ androsta-1,4-diene-3-one-17~-carboxylic acid (200 mg) and tricaprylmethylammonium chloride (200 mg) were added to 5 ml of saturated aqueous NaHC03. A solution of 100 mg of l-bromoethyl ethyl carbonate in 10 ml of methylene chloride was added. The mixture was stirred at 45C for 20 h, diluted with 10 ml of methylene chloride and isolated and purified in the same way as in procedure E yielding 254 mg of l'-ethoxycarbonyloxyethyl 6C~-difluoro-llB-hydroxy--16~17~- r( l-methylethylidene)bis(oxy)~ - androsta-l,4-diene-3-one--17~-carboxylate. The purity (HPLC) was 97.4% and the ratio epimer A/B, 60/40.
G. 6C~9~-Difluoro-llB-hydroxy-16~,17~- ~(l-methylethylidene)bis(oxy)~
androsta-1,4-diene-3-one-17B-carboxylic acid (200 mg), l-bromoethyl ethyl carbonate (135 mg) and triethylamine (275 mg) were dissolved in 20 ml of dimethylformamide. The mixture was stirred at 80C for 3 h, diluted with 200 ml of methylene chloride, washed with water, dried and evaporated. The crude product was purified in the same way as in 18 133~845 procedure A yielding 69 mg of l'-ethoxycarbonyloxyethyl 6~,9~-difluoro-~ -hydroxy-16~,17~- r(l-methylethylidene)bis(oxy)l androsta-1,4--diene-3-one-17B-carboxylate. The purity (HPLC) was 97.8% and the ratio epimer A/8, 48/52.
Exempel S. l'-Acetoxyethyl 6~,9~-difluoro-llB-hydroxy-16~,17~-~(l-methylethylidene)bis(oxy)] androsta-1,4-diene-3-one-17B-carboxylate.
6~,9~-Oifluoro-llB-hydroxy-16O~17~- [(l-methylethylidene)bis(oxy)) androsta-1,4-diene-3-one-17B-carboxylic acid (500 mg) and potassium hydrogen carbonate (575 mg) were dissolved in 40 ml of dimethylformamide. l-chloroethyl acetate (1 ml) was added and the reaction mixture was stirred at room temperature for 40 h. The reaction mixture was poured ;nto 50 ml of water and extracted with methylene lS chloride. The extract was washed with aqueous sodium hydrogen carbonate and water, dried and evaporated. The residue was chromatographed on Sephadex LH-20 column (72x6.3 cm) using chloroform as mobile phase. The fractions 1755-2025 and 2026-2325 ml were collected and evaporated.
The solid product from fraction 1755-2025 ml was further purified by chromatography on a sephadex LH-20 column (76x6.3 cm i.d.) using a mixture of heptane-chloroform-ethanol, 20:20:1, as mobile phase. The fraction 2505-2880 ml was collected and evaporated. the residue was dissolved in methylene chloride and precipitated with petroleum ether leaving 167 mg of solid product (A). The purity determind by HPLC was 99.1%. Melting point 238-59C. !~u~2~5 = +94 (c=0.192; CH2C12). The molecular weight was 524.
The solid product from fraction 2026-2325 ml above was further purified by chromatography in the same way as above. The fraction 5100-5670 ml was collected and evaporated. The residue was dissolved in methylene chloride and precipitated with petroleum ether yielding 165 mg of solid product (8). The purity determined with HPLC was 99.4%. Melting point 261-65C. ~]D5 = +34 tc=0.262; CH2C12). The molecular weight was 524.
The lH-NMR spectra of A and B are nearly identical with the exception of the methine quartet from the ester group which is shifted 0.16 ppm downfield in compound B compared to A. The fragmentation patterns of A
and B in electron impact mass spectra are identical apart from the intensities of the mass peaks. These spectroscopic properties of A and B
indicate that they are epimers due to the chiral centre in the ester group.
Exemple 6-88. The substance given in Table 1-3 below were prepared, isolated and purified in a manner analogous to that described in Examples 4 and 5.
13348~5 ,, ~, -- -- -- _ _ ~ ~o u~ o In U~ o ~ n co o \ / a) ~ In ~ u~ u~ O n o u~
m ~ ~ ~ ~ O co ~ ~
oo o~ ~ ~ o o ~r ~ oo ~ ~D
~ ~ ~ a) o 8~ ~ 3 ~' C3 ,~,\
) \
~) ~ o o ~r ~ ~o oo ~ --mr' ~ N~ ~ O 'J~, ~ ~ ~ r U~ 1- 0 /\
~D 00 ~ ~ I I ~ ~ ~u ~ a) o ~--8~ ~ ~ N ~ ~ 00 N 0 ~C~ N N N N N ~I
p, ~ m ~ m ~ m ~ m ~o ;_ _ ~ ~ ~ ~ ~ ~ ~ ~ ~) U
X ~ ~C :C -- --U U
/ \
~o o o '`' o= I I _ _ >~- -x ~ - - X
O ~ X
~h `~ ~
a) ~ ~ O o ~ c~
o X
` - 21 133~845 ~ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ c E u-) ~n o o o o m o o o O -- N r~ C~l O O 1~ U'~ O O Lr) O ~D IS) O 0 0 C~ 0 c E
U~ o U~ o U~ o U~ o o U~ o~ o U~ o c ~
D OD ~ ~ O O O O C~ 00 0 C~ 0 ~D ~D O O
-_ _~ ~D 0~ ~ ~ O O O O ~ C~ o o o O 0CO C~ 0 ISI U~ _ r U C~J
~ _ OOOOOOOOOOOOOOOOOO
D 01 ) _ 00 0 O- 0 ~1 _ ~D 0 O~ u~ _ Ir) o ~ o ~5 o ~ cn ~ D cn ~ o u~ o ~ o c~ ~ a ~ 0 ~
T + + + + + _ + _ + _ + + + + + + + +
O1~ N 1~ ~ ~ ~ t~ _ O a~ 1~ _ O
o I I I I O
~a) o d- O O ~ In u~ d 1~ Il~ O C~
S ~J~J _ _ ~ 1 C~l C~J ~J N C~
L
a~
E c~
_ ct: m I cC m ~ n cc m ~ cc m ~: m ~ m ~)OOOOOOOOOOOOOOO
~r) I
tY I I C) V <--~ ~ V ~_) o c) ~ ~ ~ ~ I I I ~ I I :C
C C~l o -- a .
a) ~ d~ 1~) D r~ a~ O _ N ~) ~ Ir') ~9 1~ 00 Cl~ O
~ ,a C~ .
- J
-- . 22 1334845 C E O ~ O O
O ~ O O O~ ~ ~ O
_ o a~
o U~ o U~ U~ o U~
O ~ I~ O ~ S
aJ O C~ 0 0 ~
a,., _ D
_ O
v~ c D E
a1 o ao co oo a~ o E
~ _ ~ . .
_ O
O ..
N C~J C~ D 00 ~ O
O
N
aJ
O
c C . , o ._ ~ C --~ ~ S S
N O ~1 _ o o o o o o Sa)C~
O ~ O 00 0 ~ t O N ~D O ~1 T + _ + + + + ~ C _ _D
+ ~ ~ ~ ~O
c ~ D DE
~ o o c~ s a s E ~ ~E
o o 1~ o o~ x ~0 E ~ E E O
" _ _ _ ~J N C`J O O O O
O O O O
~ ~ t ~_ ~ O ~ O O
E m cr~
_ + ~: a~ + ~ a: I s s ~r cc u o c ~ ~ c v ._ ~.. . ~
v~ v)v~
E E
t~ ~ ~ E E E
. .
^ ^ -- ~ ~ ~ ~ ~ X ~ ~ X
tr I I I ~ O O~_ X ~ X X
T I T -r O O O O O O O
E E E EE
~ ~ ~ ~ ~3 U~ T _ _ _ __ tY I I I T I I ~ O OO O O
O O O O O
N N N N N
T
J J J J J
X X X X
~ _ S ~ ~ S
C CL ~ C~
~ N ~O ~ a1 aJ tlJ
c o C C C C C
X LL L~ LL LL L~ ~ ~
--E~ ) ~) ~ ~ ~) _ N ~ ~ u~
~ ~O
1334~45 E ~r) o o o ~
o ~ o ~ o ~ o U~ ~ I~
~ J - E
o- o U ~ o o U~ o O
~ ~ _ ~ -- ~ 0 0 ~ C~J _ / \ ~ O ~1 _ N ~ C~ L~
O O
i I ~
O E _ ~ N Ot) O 00 ~0 ~D N O 0 I t J -- ~ ~U O O ~ ~ ~t d ~ ~ u~ ~o o 1/ ~
\
0 C~ ~D ~ ~ O 0~
O ~ 0 0 ~ eJ ~ ~ ~ U~ D
. o o O O O C- ~:
11 S + + + + + + +
.0 ~
00 Lt') O ~_ E E
O O ~ o~ l L ~ ~ L~ D oO v~
~ a~ ~ o L~) ~) 00 0 O~ E ~ ~ L ~ ~ L~ D t~ ~ ~ o ~ 'Q O
v ~( E cn a~ L
) \ v) cn V~
E E
~ ~ ~ ~ ~ ~ ~ ~ ~ Ln ID -- -- -- ~ ~) I
IY I t~ ~ O I I ~r~J 1~ 1~1 X X
) O O O O O _ _ O= _ ~) ~ ~ ~ ~ ~ ~) ~
~ I I I I I I I I I I o o CY~J~I I ~_) O ~ O O ~ O O N N
O ~ /-- N C~l N N N N N N
V ~ N N N N N N N N J
~) I I I I I I I I
n-S~_-- X X I I I I I I I I 1 O I r ~ X I ~ 1~ c C
\ \ O O
N ~ ~ - C) aJ \~ Q a~ O _ N ~ ~ L
24 1 133~5 _ _ ~ _ _ _ _ ~ ~ _ _ ~ E u~ o o o u~ o o n -- O -- ~ ~O O 1~ 1~ ~ O U~ O C~l E , ~ N ~J N ~ ~
j ~ o ~n o u- u~ O O O O o O u~ ~ O O ~ ~ O ~n ~, ~ ~ C`J ~ a:~ o o o o c~ oo ~ _ ~ O O O ~ ';t N C~J ~J t~J
C~ 3 ~ / r--/\ ~
N C~ CO O O 0 0 0 ) 00 O 1~1 0 0 ~ d- ~J NC~J N ~:t Ct ~t O '~ I E
O
O
\ U~ C~J
I _ o o o o o o o o o o O C~ D O ~) O d -- d-11 I + + + + _ + _ + _ +
~ ~ + + +
O
N ~0 _ u~ ~D N ~ r) O
S _ _ ~ J ~I N-- N _ N
N _ L
E I I I I ~t: m ~ a~
oo Y I I ' ~D ~ ~ ~ ~
Q!~ -~ e ~ ~ ~ ~ ~ I~) I I I I I
Y I T I I T
I T
I T I I --~ ~ I I I I I
O O C~
o '~ I CY I ~ I I I I I I I I
o u~
V
I t~ _ -- I N
\ ~! ~
~-- X~ X~
O I \ ~ X
a ~ O E ~
_ n~ o ~ n 1,~34845 _ _ _ _ ~ ~r ~ _ N N N N N ~I N N N U') C E Ou~ o o -- o1~ ~ oou ~ o o1~ o o u o- o ~ ~ O O
.~ ~C~J ~ _ N N~) N t~ ~t ~ ~D ~ u ~ ID U~
c E '' ' ' l l l ' ' ' oo o o oU~ o o U~
_ O ~D O N n ~ N ~ O O O 0 ~ ~
al o _ 1~ 1~ JC~J ~ N ~) et ~ u~ ~ ~ C) ~ ~ N
C~ ~ N N _ -- N
C ~
cn c ~ ~ N C~ N N O O 00 ~ ~ ~ OD
--a~ u N N '~ ~ ~ CO N N O O C:) 0 el~ ~ 00 0 s U u~
U~ ._ _ O C~J
~ In u~ r~ cn ~o ' o O a~
O C~J 1~ 1~ 1-- D tO 1~ 'J- 1~ O ~ _ 1~) 0~ N O 1'~ 0 Il I + + + + + + + + _ + _ + + + _ + _ +
U ~ + + + +
-cr.
O N C~ O C~ 00 'J u~
U~ 1~ O O _ _ ~ ~D ~0 00 '~ N ~t _ _ '.~J 00 N _ -- _ -- _ N _ _ _ -- N _ _ N N
L
a~
E m m ~ m, I I I I I + + ~: m ~ m c~: m ~: m cr N N N
~O I I -- -- -- -- I T 5 1 ~ :r -- -- I I -- --O O O O O O O O O O O O O O O O
I T I I I I T I I I I I .I
S
N N N N N N N N N N N N ~`J
N ^ ^ ^ ~ _ ~ ~ ~ _ _ _ ~ _ ~Y N N I ~`J I N C~l C`J I C~l ~`J C~l I I N C~J N C~J
T
_ I
N N C~l N C~l ~! I I -- I -- I I I -- I I I -- -- I I I I
-- N N N N N
~ I I I I I
~ _ _ _ _ ~
c ._ N
X I I T I I I 1~_ 1~ I I I I I I I I I I
o ~ ~11 .
-- E . 0~ .-- N .. ~ ~ u~ oo ~ O _ N 1~ ~ n 26_~ 33~18~15 _ ~ N N N N Ir~ N
o -- o o -) o ~ U~ o ~n o u~ o o c E ' ' ' I ' I ' Oo ~ ~ Lr o U~ o o _ o o o _ CO ~ ~ ~" O ~D N ~ . el~
O ~In ~ ~ I t~ ~) 1~ N ~ ' _ _ ID
~r) . N N ~) ~ .
S ~
~_ ~ ~ ~ el- et 00 0 00 CO C~ N N N N
V~
............. _ ~COCO0~ NNNN
E
c ._ _ ~
N ~_ N~N~ 000000000000 r-~ON ~.~N~O~I _O
~III ++_++++_++++ ~N
~ ~ + + O ~-_ NO
O _ N~N_OO~_~N -r ~ N~N_~ O ~
o IIIIIIIIIIII Ca~aJs O~-~N~ O~Q
Q NNN~__~NI CS~
NNNN__ NN_NN ~SS~
I _ E G~
o E Ct~ a~ E ~ ~ -- E
o o o o V7 o o E r~l _ ~ (n ~n E
o ~ o ~ _ N N N -- ~) O
_ _ _ s , E E '--~O I I I I I I I I I I I I I I c ~ O
T 1. I I l I T ~ 1 Q _ _ S
OOOOOGOOOOOOO ~S__ SCl~
~ ~ _ I I I I I I I I I I I I O Cv1 c C ~
~ _ ~ ~ E
E E E Lr ~t I I I I I I I I I I I I I ~) N ~ U'~ X
X X X
~D 1~ N O
-- -- -- -- --__ NNNNNNN E E E E E
N II NNNNNNN
II~IIIIIIIII --___ _ ~ <_,~ ~) ~ ~ ~ ~ O O O O O
O O O O O
~NNNN
~ II IIIII
II NN
~IINN T IIIIII XXXXX
~ S S S S S
c Q~QQQ
_ N ~
X LL ~ L~ ~ LL ~ ~ ~ ~ ~ L- L~ ~ O Cl O O O
~ ~IJ
-- EQ ~o r~ oo ~ o _ ~
Example ~9 . Pharmaceutical Preparations The following non-limitative examples illustrate formulations intended for different topical forms of administration. The amount of active steroid in the percutaneous formulations are ordinarily 0.001-0.2% (w/w), preferably 0.01-0.1% (w/w).
Formulation 1, Ointment Steroid, micronized0.025 9 Liquid paraffin 10.0 9 White soft paraffinad 100.0 9 Formulation 2, Ointment Steroid 0.025 9 Propylene glycol 5.0 9 Sorbitan sesquioleate5.0 9 Liquid paraffin 10.0 9 White soft paraffinad 100.0 9 For,nulation 3, Oil in water cream Steroid 0.025 9 Cetanol 5.0 9 Glyceryl monostearate5.0 9 Liquid paraffin 10.0 9 Cetomacrogol 1000 2.0 9 Citric acid 0.1 9 Sodium citrate 0.2 9 Propylene glycol 35.0 9 Water ad 100.0 9 ~ 28 1334845 Formulation 4, Oil in water cream Steroid, micronized 0.025 9 White soft paraffin 15.0 9 Liquid paraffin 5.0 9 Cetanol 5.0 9 Sorbimacrogol stearate 2.0 9 Sorbitan monostearate 0.5 9 Sorbic acid 0.2 9 Citric acid 0.1 9 Sodium citrate 0.2 9 Water ad 100.0 9 Formulation 5, Water in oil cream Steroid 0.025 9 White soft paraffin35.0 9 Liquid paraffin 5.0 9 Sorbitan sesquioleate5.0 9 Sorbic acid 0.2 9 Citric acid 0.1 9 Sodium citrate 0.2 9 Water ~ ad 100.0 9 Formulation 6, Lotion Steroid 0.25 mg Isopropanol 0.5 ml Carboxyvinylpolymer 3 mg NaOH q.s.
Water ad 1.0 9 29 13348~5 Formulation 7, Suspension for injection Steroid, micronized 0.05-10 mg Sodium carboxymethylcellulose7 mg NaCI 7 mg Polyoxyethylene (20) sorbitan monoleate O.S mg Phenyl carbinol 8 mg Water, sterile ad 1.0 ml Formulation 8, Aerosol for oral and nasal inhalation Steroid, micronized 0.1 % w/w Sorbitan trioleate 0.7 % w/w Trichlorofluoromethane 24.8 % w/w Dichlorotetrafluoromethane24.8 % w/w Dichlorodifluoromethane49.6 % w/w Formulation 9, Solution for atomization Steroid 7.0 mg Propylene glycol 5.0 9 Water ad 10.0 9 Formulation 10, Powder for inhalation A gelatin capsule is filled with a mixture of Steroid, micronized 0.1 mg Lactose 20 mg 0 The powder is inhaled by means of an inhalation device.
Pharmacology _ The affinity of the new androstane-17~-carboxylic acid esters to the glucocorticoid receptor All steroids according to the present invention are physiologically active compounds. The affinity of the novel androstane-17B-carboxylic acid esters to the glucocorticoid receptor has been used as a model for determination of the anti-inflammatory potency. Their receptor affi-nities have been compared to budesonide ~[22R,S]-16~,17~-butylidenedioxy-llB,21-dihydroxypregna-1,4-diene-3,20-dione) a highly active glucocorti-coid with a favourable ratio between local and systemic effects (Thalén and Brattsand, Arzneim.-Forsch. 29, 1687-90 (1979)).
Male Sprague-Dawley rats, one to two months of age, were used throughout the investigation. The thymus was removed and put into ice-cold saline.
The tissue was homogenized in a Potter Elvehjem homogenizer in 10 ml of a buffer containing 20 mM Tris, pH 7.4, 10 % (w/v) glycerol, 1 mM
EDTA, 20 mM NaMoO4, 10 mM mercaptoethanol. The homogenate was centri-fuged for 15 min at 20,000 x 9. Portions of the 20,000 x 9 supernatant (230 ~1) were incubated for abowt 24 h at 0C with lOC ~1 phenylmethyl-sulphonylfluoride (an esterase inhibitor, final conc. 0.5 mM), 20 ~1 unlabelled competitor and 50 ~1 3H-labelled dexamethasone (final conc.
3 nM). Bound and free steroid were separated by incubating the mixture with 60 ~1 2.5 % (w/v) charcoal and 0.25 % (w/v) dextran T70 suspension in 20 mM Tris, pH 7.4, 1 mM EDTA, and 20 mM NaMoO4 for 10 min at 0C.
Following a centrifugation at 500 x 9 for 10 min, 230 ~1 of the super-natant was counted in 10 ml Insta-Gel in a Packard scintillation spectro-photometer. The supernatants were incubated with a) [3H]dexamethasone alone, b) [3H]dexamethasone plus 1000 fold excess of unlabelled dexa-methasone and c) [3H]dexamethasone plus 0.03-300 fold "excess" of compe-titor. The nonspecific binding was determined when 1000 fold excess of unlabelled dexamethasone was added to [3H]-labelled dexamethasone.
The radioactivity bound to the receptor in the presence of competitor divided by the radioactivity bound to the receptor in the absence of competitor multiplied by 100 gives the percentage specific binding of labelled dexamethasone. For each concentration of a competitor the per-133~845 . 31 centage specifically bound radioactivity is plotted against the log of concentration of competitor. The curves are compared at the 50 %
specific binding level and referenced to budesonide, which is assigned a relative binding affinity (RBA) of 1.
Table 4. Table summarizing relative binding affinities (RBA) to the glucocorticoid receptor of some of the investigated compounds.
Compound according RBA
to Ex. No.
Budesonide . 4 epimer B 0.30 5 epimer B 0.17 27 0.50 3~ 0.04 0.20 64 0.05 69 0.44 84 1.03 87 0.63
The object of the invention of Application Serial No.
505,744 is to provide a glucocorticosteroid which possesses high anti-inflammatory potency at the place of application and low glucocorticoid systemic potency. This divisional Application is concerned with a process for preparing certain compounds useful as intermediates in the preparation of the glucocorticosteroids of Application Serial No. 5~5,744.
Backqround Art It is known that certain glucocorticosteroids (GCS) can be used for local therapy of inflammatory, allergic or immuno-logic diseases in respiratory airways (e.g. asthma, rhinitis), in skin (eczema, psoriasis) or in bowel (ulcerative colitis, Morbus Crohn). With such local glucocorticoid therapy, clinical advan-tages over general therapy (with e.g. glucocorticoid tablets) are obtained, especially regarding reduction of the unwanted glucocorticoid effects outside the diseased area. To reach such clinical advantages, in e.g. severe respiratory airway disease, GCS must have a suitable pharmacological profile. They should have high intrinsic glucocorticoid activity at the application site ~' - 1~34845 but also a rapid inactivation by e.g. hydrolysis in the target organ or after uptake into the general circulation.
Since binding of GCS to the glucocorticoid receptor is a pre-requisite for their anti-inflammatory and allergic effects to occur, the ability of steroids to bind to their receptor(s) can be used as an adequate method for determining the biological activity of GCS. A direct correlation between the affinity of GCSs to the receptor and their anti-inflammatory effects has been shown using ear edema test in the rat. [Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 ~,17~ -acetal substituted gluco-corticoids. E. Dahlberg, A. Thalén, R. Brattsand, J-A Gustafsson, U. Johansson, K. Roempke, and T. Saartok, Mol. Pharmacol. 25 (1984), 70.]
Disclosure of the Invention ___________________________ The invention of Application Serial No. 505,744 is based on the observation that certain 3-oxo-androsta-1,4-diene-17~-carboxylic acid esters possess high binding affinity to the glucocorticosteroid receptor. The compounds can be used for the treatment and control of inflammatory conditions.
The compounds of the invention of Application Serial No. 505,744 are characterized by the formula - 2a - - 23940-529D
OlR3 C=O
H0 ~ = 0 ~ CRlR2 I
0~
wherein the 1,2-position is saturated or is a double bond Xl is selected from hydrogen, fluorine, chlorine and bromine X2 is selected from hydrogen, fluorine, chlorine and bromine Rl is selected from hydrogen or a straight or branched hydrocarbon chain having 1-4 carbon atoms R2 is selected from hydrogen or straight and branched hydrocarbon chains having 1-10 carbon atoms and O O
.. ..
R3 is selected from CR4R50C~6 or CR4R50 6 Y is 0 or S
R4 is selected from hydrogen, straight or branched hydrocarbon chains having 1-10 carbon atoms or from phenyl R5 is selected from hydrogen or methyl and R6 is selected from hydrogen, straight or branched, saturated or unsatur-ated hydrocarbon chains having 1-10 carbon atoms, an alkyl group substituted by at least one halogen atom, a heterocyclic ring system containing 3-10 atoms in the ring system, -(CH2)m CH(CH2)n (m =
_ 5 0,1,2; n = 2,3,4,5,6), phenyl or benzyl groups which are unsubstitut-ed or substituted by one or more alkyl, nitro, carboxy, alkoxy, halo-gen, cyano, carbalkoxy or trifluoromethyl group(s), provided that when R2 is hydrogen Rl is methyl.
The individual stereoisomeric components present in a mixture of a stero-id having the above formula (I) can be elucidated in the following way:
H0 ~ _ 0, C~
CH3 I Rl (II; epimer S) CH C = 0 R
H0 ~ _ ~ C~
~, ~ (III; epimer R) The individual stereoisomeric components present, in a mixture of stero-id 17~-carboxylic acid esters having the formulas StCOCR4R50CR6 (IV) or O O
Il 11 StCOCR4R50CYR6 -(V) '. -1334845 where St is the steroid moiety, can be elucidated in the following way 8 ~4e 8 R4,01 StCOC,OCR6 StCOCOCR6 VI VII
and StCOCOCYR6 1l ~41l VIII IX
In diasteroisomers like II, III, VI, VII, VIII and IX, the configuration differs only at one out of several asymmetric carbon atoms. Such dia-stereoisomers are denoted epimers, Alkyl in thedefinitions above is a straight or branched hydrocarbon chain with 1-5 carbon atoms, preferably l-4 C.
Alkoxy in the definition above is a group -0-alkyl wherein the alkyl moiety has the above given definition.
Halogen in the definition above is preferably a chlorine, bromine or fluorine atom.
Carbalkoxy in the definition above is a group -C00-alkyl wherein the alkyl moiety has the above given definition.
Heterocyclic ring system is a ring system containing as hetero atoms N, 0 or S.
Preferred systems are pyrryl, pyrridyl, pyrimidyl, pyrazinyl, furyl, pyranyl, benzofuranyl, indolyl and thienyl.
Particular compounds of the invention which are preferred:
J
l'-Ethoxycarbonyloxyethyl 6~,9~-difluoro-llB-hydroxy-16~,17~-[(1-methyl-ethylidene)bis(oxy)]-androsta-1,4-diene-3-one-17~-carboxylate, the epi-meric mixture A + B and epimer B.
l'-isopropoxycarbonyloxyethyl 9~-fluoro-11~-hydroxy-16~,17~-[(1-methyl-ethylidene)bis(oxy)]-androsta-1,4-diene-3-one-17B-carboxylate, epimer B.
l'-propoxycarbonyloxyethyl 6~,9~-difluoro-11~-hydroxy-16~,17~-[(1--methylethylidene)bistoxy)]androxta-1,4-diene-3-one-17~-carboxylate, epimer B.
l'-isopropoxycarbonyloxyethyl 6~,9~-difluoro-11~-hydroxy-16~,17~-[(1--methylethylidene)bis(oxy)]androsta-1,4-diene-3-one-17~-carboxylate, epimeric mixture A + B and epimer B.
l'-Acetoxyethyl (20R)-9~-fluoro-11~-hydroxy-16~,17~-propylmethylene-dioxyandrosta-1,4-diene-3-one-17~-carboxylate, epimer B.
l'-Ethoxycarbonyloxyethyl (22R)-9~-fluoro-11~-hydroxy-16~,17~-propyl-methylenedioxyandrosta-1,4-diene-3-one-17~-carboxylate, epimer B.
l'-i,opropoxycarbonyloxyethyl ~20R)-9~-fluoro-11~-hydroxy-16~,17~--propylmethylenedioxyandrosta-1,4-diene-3-one-17~-carboxylate, epimer B.
l'-Ethoxycarbonyloxyethyl (20R)-6~,9~-difluoro-11~-hydroxy-16~,17~-propylmethylenedioxyandrosta-1,4-diene-3-one-17B-carboxylate, epimeric mixture A + B and epimer B.
Methods of Preearation _ The compounds of the invention are prepared by the oxidation of a com-pound of the formulas X, XI and XII to the corresponding 17~-carboxylic acid:
fH2-OR7 C=O
HO ~ - - ~ CR R
0~
Xz ~ ```R
XI
0~
C=O ~ R
HO ~ - ~ C~-~R XII
~, 0~
wherein the solid and broken lines between C-l and C-2 represent a single or double bond, ~, 1339~8452394O-529D
Xl, X2, Rl and R2 have the meaning given above, and R7 is hydrogen or an acyl group with 1-10 carbon atoms arranged in a straight or branched chain.
The 17~-carboxylic acids then are esterified to give compounds character-ized by the formula I-IX, wherein --- Xl, X2, Rl, R2 and R3 have the meaning given above.
The process of converting a compound of formulas X, XI
or XII to the corresponding 17-carboxylic acids is carried out in a suitable oxygenated hydrocarbon solvent such as a lower alkanol. Methanol and ethanol are preferred, particularly the former. The reaction medium is made slightly alkaline by the addition of a suitable weak inorganic base such as an alkali metal carbonate, for example sodium, lithium or potassium carbonate. The latter is preferred. The conversion o~ a compound of formula X, XI or XII to a 17~-carboxylic acid of formula I, II or III (R3=H) takes place at ambient temperatures, i.e. 20-25C.
The presence of oxygen is necessary for the reaction. Oxygen can be supplied by bubbling a stream of air or oxygen into the reaction mixture.
The oxidative degradaticn of the 17~ side-chain of compounds of formula X, XI and XII to the correspondi~g 17~ carboxylic acids can also be carried out with periodic acid, sodium h~pobromate or with sodium bis-muthate. The reaction is performed in a mixture of water and a suitable oxygenated hydrocarbon solvent such as a lower ether. Dioxane and tetra-hydrofurane are preferred, particularly the former.
The parent 17~-carboxylic acids of compounds of formula I, II and III
(R3=H) may be esterified in known manner to provide 17~ carboxylate esters according to the invention. For example, the 17~-carboxylic acid may be reacted with an appropriate alcohol and a carbodiimide, e.g.
dicyclohexylcarbodiimide, in a suitable solvent such as diethylether, tetrahydrofurane, methylene chloride or pyridine advantageously at a temperature of 25-100C. Alternatively, a salt of the 17~-carboxylic acid with an alkali metal, e.g. lithium, sodium or potassium, a salt ` - -8 13348~5 of a quaternary ammonium compound, such as a salt of triethyl-or tri-butylamine, or tetrabutylammonium, may be reacted with an appropriate alkylating agent, for example an acyloxyalkylhalide or haloalkyl alkyl-- carbonate preferably in a polar solvent medium such as acetone, methyl-ethylketone or dimethyl formamide, dimethyl sulphoxide, methylenechlo-ride or chloroform, conveniently at a temperature in the range 25-100C.
The reaction may also be performed in the presence of a crown ether.
The crude steroid ester derivatives formed are after isolation purified by chromatography on a suitable material, for instance cross-linked dextran gels of Sephadex~ LH-type with suitable solvents as eluants, e.g. halogenated hydrocarbons, ethers, esters such as ethyl acetate or acetonitrile.
The individual epimers, which are formed at the acetalisation of the 16~,17~-hydroxy groups or at the esterification of the 17B-carboxylic acids, possess practically identical solubility characteristics. Accord-ingly, they have turned out to be impossible to separate and isolate from the epimeric mixture by conventional method for resolution of ste-reoisomers, e.g. fractionated crystallization. In order to obtain theindividual epimers separately the stereoisomeric mixtures according to the formulas I, IV and V above are subjected to column chromatography, thus separating the epimers II, III, VI, VII, VIII and IX in view of different mobility on the stationary phase. The chromatography may be carried out for instance on cross-linked dextran gels of the type Sephadex~ LH, e.g. Sephadex~ LH-20 in combination with a suitable organic solvent as eluting agent. Sephadex~ LH-20, prepared by Pharmacia Fine Chemicals AB, Uppsala, Sweden, is a beadformed hydroxypropylated dextran gel wherein the dextran chains are cross-linked to give a three-dimen-sional polysaccharide network. As eluting agent, halogenated hydrocar-bons e.g. chloroform or a mixture of heptane-chloroform-ethanol in the proportions 0-50:50-100:10-1 has successfully been used, preferably a 20:20:1 mixture.
As starting materials for the compounds of the invention compounds of the formulas X, XI and XII are used. They are prepared by reaction of compounds with the formula 9 13348~5 C=O
H0 ~ -- O0H
~ XIII
0~
wherein the solid and broken lines between C-l and C-2 represent a single or double bond, and Xl, X2 and R7 have the meaning given above, with an aldehyde of the formula / H
=C\R2 wherein R2 has the meaning given above.
The aldehyde is preferably acetaldehyde, propan~l, butanal, isobutanal, pentanal, 3-methylbutanal, 2,2-dimethylpropanal, hexanal, heptanal, octanal, nonanal and dodecanal. The reaction is carried out by adding the steroid to a solution of the aldehyde together with an acid cata-lyst, e.g. perchloric acid, p-toluene sulphonic acid, hydrochloric acid in an ether, preferably dioxane, or halogenated hydrocarbons, prefer-ably methylene chloride or chloroform.
Compounds X, XI and XII are also prepared by transacetalisation of the corresponding 16~,17~-acetonides CIH20R7 H0 ~ ~ - = 8 ~ C 3 ~
0~
. ' - lO - 1334845 23940-529D
wherein the solid and broken lines between Cl and C2 represent a single or double bond and Xl, X2 and R7 have the meaning given above with an aldehyde of the formula H
\ R
wherein R2 has the meaning given above.
This divisional application is concerned with a process for the preparation of a compound of the formula C=O
CH ~ ___O = = R2 ~=~
O
or a stereoisomeric compound thereof, in which formula the 1,2-position is saturated or is a double bond Xl is selected from hydrogen, fluorine, chlorine and bromine X2 is selected from hydrogen, fluorine, chlorine and bromine R2 is selected from straight and branched hydrocarbon chains having 1-10 carbon atoms and R7 is hydrogen or an acyl group with 1-10 carbon atoms arranged in a straight or branched chain, characterized by reaction of a steroid compound of the formula ~ 23940-529D
C=O
H ~ C`--~ O >C C C H 3 o~'~
with an aldehyde compound of the formula / H
O-C/
wherein X1~ g2~ R2~ R7 and have the meanings given above, in the presence of perchloric acid.
The aldehyde is preferably acetaldehyde, propanal, butanal, isobutanal, pentanal, 3-methylbutanal-, 2,2-dimethyl-propanal, hexanal, heptanal, octanal, nonanal and dodecanal. The reaction can be carried out by adding the steroid to a solution of the aldehyde together with a strong inorganic acid as catalyst, preferably perchloric or hydrochloric acid, in an ether, prefer-ably dioxane or tetrahydrofuran, a halogenated hydrocarbon, preferably methylene chloride or chloroform, an aromatic hydrocarbon, preferably toluene, an alicyclic hydrocarbon, preferably cyclohexane or an aliphatic hydrocarbon, preferably heptane or isooctane, under the latter conditions eliminating the chromatographic step for preparation of the epimers III and XII.
lOa ~~ 23940-529D
Pressurized aerosols for steroids are intended for oral or nasal inhalation. The aerosol system is designed in such a way that each delivered dose contains 10-1000 ~g, preferably 20-250 ~g of the active steroid. The most active steroids are administered lOb 'C
133~845 in the lower part of the dose range. The micronized steroid con-sists of particles substantially smaller than 5 ~m, which are suspended in a propellent mixture with the assistance of a dispersant, such as sorbitan trioleate, oleic acid, lecithin or sodium salt of dioctylsulphosuccinic acid.
Working Examples _ _ _ _ _ _ _ _ _ _ _ _ _ _ The invention of Application Serial No. 505,744 and of this divisional application will be further illustrated by the following non-limitative examples. In the examples a flow-rate of 2.5 ml/cm2-h 1 is used at the preparative chromatographic runs.
Molecular weights are in all examples determined with electron im-pact mass spectrometry and the melting points on a Leitz Wetzlar hot stage microscope. All HPLC analyses (HPLC = High Performance Liquid Chromatography) were performed on a Waters ~Bondapak C18 column (300x3.9 mm internal diameter) with a flow-rate of 1.0 ml/
min and with ethanol-water in ratios between 50:50 and 60:40 as mobile phase, if not otherwise stated.
Example 1. This example sets forth a process for preparing (22~S)-, (22R)- and (22S)-11~,16~,17~,21- tetrahydroxypregna-1,4-diene-3,20-dione 16~,17~-acetals.
Preparation of (22RS)-, (22R)- and (22S)-16~,17~-butylidenedioxy-6~,9~-difluoro-11~,21-dihydroxypregna-1,4-diene-3,20-dione.
A. To a suspension of 1.0 g of 6~,9~-difluoro-11~,16~, 17~,21-tetrahydroxypregna-1-4-diene-3,20-dione in 500 ml of methylene chloride 0.32 ml of freshly distilled n-butanal and 2 ml - lla - 1334845 23940-529D
72% perchloric acid were added. The reaction mixture was allowed to stand for 24 h at room temperature under stirring. The reaction mixture was washed with 10% aqueous potassium carbonate solution and water, dried over sodium sulphate and evaporated.
The residue was dissolved in ethyl acetate and precipitated with petroleum ether leaving 883 mg of (22RS)-16~,17~-butylidenedioxy-6~,9~-difluoro-11~,21-dihydroxypregna-1,4-diene-3,20-dione.
HPLC-analysis showed 99% purity and the ratio 16:84 between the 22S- and 22R-epimers. Molecular weight: 466 (calculated 466.5).
` - -13348~5 The (22RS) epimeric mixture was chromatographed on Sephadex LH-20 column (76 x 6.3 cm) using heptane:chloroform:ethanol, 20:20:1, as mobile phase. The fractions 12315-13425 ml (A) and 13740-15690 ml (B) were collected and evaporated and the residue dissolved in methylene chloride and precipitated with petr.-ether. Fraction A gave 62 mg of (22S)- and fraction B
687 mg of (22R)-16a,17a-butylidenedioxy-6a,9a-difluoro-11~, 21-dihydroxypregna-1,4-diene-3,20-dione. The (22S)-epimer:
Molecular weight 466 (calculated 466.5), m.p. 196-200C.
The (22R)-epimer: Molecular weight 466 (calculated 466.5), m.p. 169-72C.
B. To a solution of 1.0 g of 6a,9a-difluoro-11~, 21-dihydroxy-16a,17a-[(1-methylethylidene)bis(oxy)] pregna-1,4-diene-3,20-dione in 500 ml of methylene chloride was added 0.30 ml freshly distilled n-butanal and 2 ml of 72% perchloric acid. The reaction mixture was allowed to stand for 24 h at 33C under stirring, extracted with aqueous potassium carbonate and water, dried over sodium su~phate and evaporated. The res-idue was dissolved in methylene chloride and precipitated with petr.-ether yielding 848 mg of (22RS)-16a,17a-bUtylidenedioxy-6a,9a-difluoro-11~,21-dihydroxypregna-1,4-diene-3,20-dione HPLC-analysis showed 93% purity and the ratio 12/88 between the 22S- and 22R-epimers.
B'. To a suspension of 4.0 g of 6a,9a-difluoro-llB,21-dihydroxy-16a,17a-[(methylethylidene)bis(oxy)] pregna-1,4-diene-3,20-dione in 100 ml of heptane was added 1.2 ml of freshly distilled _-butanal and 3.8 ml of perchloric acid (72%).
~ ` 133~8~S
- 12a -The reaction mixture was allowed to stand for 5 h at room temperature under vigorous stirring, extracted with aqueous potassium carbonate and water, dried over sodium sulphate and evaporated yielding 4.0 g of (22Rs)-l6a~l7a-butylidenedi 6a~9a-difluoro-ll R, 21-dihydroxypregna-1,4-diene-3,20-dione.
HPLC-analysis showed 98.5% purity and the ratio 3/97 between the 22S- and 22R-epimers. After two recrystallisations from chloroform-petroleum ether 3,1 g of 22R-epimer was obtained, which contained only 1.1% of the 22S-epimer and 1.3% of other impurities.
C. Similarly, by following the procedure set forth in the example by substituting 6a~9a-difluoro-~ l6a~l7a~2 tetrahydroxypregna-1,4-diene-3,20-dione for llR,16a,17a,21-tetrahydroxypregna-1,4-diene-3,20-dione,9a-fluoro- and 6a-fluoro-ll R ,16a~l7a~2l-tetrahydroxypregna-l~4-diene-3~2o-dione or the corresponding 16a~l7a-acetonides non-fluorinated and fluorinated non-symmetric (22RS)-, (22R)- and (22s)-llR~l6a~
17a~2l-tetrahydroxypregna-l~4-diene-3~2o-dione 16a,17a-acetals from acetaldehyde, propanal, butanal, isobutanal, pentanal, 3-methylbutanal, 2,2-dimethylpropanal, hexanal, heptanal, oct-anal, nonanal and dodecanal are prepared.
~_ 13 1334~45 Example 2 A. Prednacinolon 16~,17a-acetonide (250 mg;0,6 mmol) was dissolved in 75 ml of CH2C12. n-Butanal (130 mg; 1,8 mmol and 70% perchloric acid (0,025ml) were added. The solution was stirred at 33C for 15 hours.
The yellow solution was washed with 2xlO ml of 10% K2C03 and 4xlO ml of H20, dried and evaporated. Yield: 257 mg (97,7%~. HPLC gave 91,1%
purity. Unreacted acetonide consists of 7,4% of the impurities. Epimer ratio 14,6/85,4.
B. Triamcinolon 16O~17~-acetonide (0,5 9; 1,1 mmol) was dissolved in 150 ml of CH2C12. n-Butanal (260 mg; 3,6 mmol) and 70% perchloric acid (0,22 - ml) were added. The mixture way stirred at 33C for 16 hours. CH2C12 was taken over into a separation funnel and the reaction flask was washed several times with 10 ml K2C03 and CH2C12, respectively. The solution was then washed with 2xlO ml of 10% K2C03 and 4xlO ml of H20, dried and evaporated. Yield: 438 mg (84,9%). HPLC gave 80,2% purity. Epimer ratio 19/81.
C. Fluocinolon 16~,17~-acetonide (0,5 9; 1,1 mmol) was dissolved in 150 ml of CH2C12. n-Butanal (260 mg; 3,6 mmol) and 70% perchloric acid (0,22 ml)were added. The mixture was stirred at 33C for 24 hours. The CH2C12 phase was taken over into a separation funnel. The reaction flask was washed several times with 15 ml of 10% K2C03 and CH2C12, respectively.
The solution was washed with 2x15 ml of 10% K2C03 and 4x15 ml of H20, dried and evaporated. Yield: 513 mg (100%). HPLC gave 97,4% purity.
Epimeric ratio 8.6/91,4.
Example 3. This example sets forth a process for preparing ll~-hydroxy-16~,17~- [(l-methylethylidene)bis(oxy)] - and (20RS)-, (20R)- and (20S)-ll~-hydroxy-16~,17a-alkylmethylenedioxyandrosta-1,4-diene-3-one-17~-car-boxylic and -4-ene-3-one-17~-carboxylic acids.
_ . 1334845 Preparation of 6~,9~-difluoro-llB-hydroxy-16~,17~-[(1-methylethylidene)-bis(oxy)]androsta-1,4-diene-3-one-17B-carboxylic acid.
A. To a solution of 1.99-9 of fluocinolone 16~,17~-acetonide in 120 ml of methanol 40 ml of 20% aqueous potassium carbonate was added. A stream of air was bubbled through this solution for about 20 h under stirring at room temperature. The methanol was evaporated and 200 ml of water was added to the residue. The solution was extracted with methylene chloride. The aqueous phase was acidified with diluted hydrochloric acid. The precipitate formed was collected by filtration and dried to yield 1.34 9 of 6~,9~-difluoro-llB-hydroxy-16~,17~-[(1-methylethylidene)-bis(oxy)]androsta-1,4-diene-3-one-17B-carboxylic acid, melting point 264-68C, molecular weight 438. The purity determined by HPLC was 94.0%.
The aqueous phase was extracted with ethyl acetate. After drying the solvent was evaporated leaving another 0.26 9 portion of acid.
Purity: 93.7%.
B. Periodic acid (15.1 9) in 16.5 ml of water was added to a solution of fluocinolone 16~,17~-acetonide (5.0 9) in 55 ml dioxane. The reaction mixture was stirred at room temperature for 20 h, neutralized with satur-ated aqueous sodium hydrogen carbonate and evaporated. The residue was dissolved in 200 ml of methylene chloride and washed with 8 x 100 ml 10% aqueous potassium carbonate. The aqueous phase was acidified with conc. hydrochloric acid and extracted with 6 x 100 ml of ethyl acetate.
After drying the solvent was evaporated. The residue was dissolved in 400 ml of ethyl acetate and precipitated with petroleum ether yielding 3.96 9 of 6~,9~-difluoro-11~-hydroxy-16~,17~-[(1-methylethylidene)bis-(oxy)]androsta-1,4-diene-3-one-17B-carboxylic acid. The purity deter-mined by HPLC was 99.5%.
C. Similarly, by following the procedure set forth in the example by substituting fluocinolone 16~,17~-acetonide for llB,16~,17~,21-tetra-hydroxypregna-1,4-diene-3,20-dione, 6~-fluoro-11~,16,17~,21-tetrahyd-roxypregna-1,4-diene-3,20-dione, and triamcinolone 16~,17~-acetonide llB-hydroxy-16~,17~-[(1-methylethylidene)bis(oxy)]androsta-1,4-diene-- 3-one-17~-carboxylic acids are prepared. By substituting the 16~,17~-acetonide group for 16~,17~-acetals between 16a-hydroxyprednisolone 6~-fluor-16~-hydroxyprednisolone, triamcinolone and fluocinolone and ~J
`- 13348~5 acetaldehyde, propanal, butanal, isobutanal, pentanal, 3-methylbutanal, 2,2-dimethylpropanal, hexanal, heptanal, octanal, nonanal and dodecanal and their 21-esters (20RS)- (20R)- and (20S)-llB-hydroxy-16~,17~-alkyl-methylenedioxyandrosta-1,4-diene- and 4-ene-3-one-17~-carboxylic acids are prepared.
Example 4. l'-Ethoxycarbonyloxyethyl 6~,9~-difluoro-11~-hydroxy-16~,17~-[(l-methylethylidene~bis(oxy)]androsta-1,4-diene-3-one-17~-carboxylate.
A. 6~,9~-Difluoro-ll~-hydroxy-16~,17~-[(1-methylethylidene)bis(oxy)]-androsta-1,4-diene-3-one-17~-carboxylic acid (600 mg) and potassium hydrogen carbonate (684 mg) were dissolved in 45 ml of dimethyl form-amide. 1-Bromoethyl ethyl carbonate (2 ml) was added and the reaction mixture stirred at room temperature overnight. Water (200 ml) was added and the mixture was extracted with methylene chloride. The combined extracts were washed with 5% aqueous sodium hydrogen carbonate and water, and the residue purified by chromatography on a Sephadex LH-20 column (72x6.3 cm) using chloroform as mobil phase. The fraction 1515-2250 ml was collected and evaporated yielding 480 mg of l'-ethoxycarbonyloxy-ethyl 6~,9~-difluoro-11~-hydroxy-16~,17~-[(1-methylethylidene)bis~oxy)]-androsta-1,4-dienc-3-one-17B-carboxylate. The purity determined by HPLC
was 98.1% and the ratio epimer A/B, 48/52. Melting point: 218-27C.
[~]2D5 = +63.2 (c=0.214; CH2C12). The molecular weight was 554.
The l'-ethoxycarbonyloxyethyl 6~,9~-difluoro-11~-hydroxy-16~,17~-(1-methylethylidene)bis(oxy)]androsta-1,4-diene-3-one-17~-carboxylate (480 mg) was chromatographed on a Sephadex LH-20 column (76x6.3 cm) using heptane:chloroform:ethanol, 20 20:1, as mobile phase. The fraction 2325-2715 ml was collected, evaporated and the residue dissolved in methylene chloride and precipitated by petroleum ether giving 200 mg of a compound (A) of purity 97.3% (determined by HPLC analysis). Melting point: 246-50C. [~]2D5 = +100.5 (c=0.214; CH2C12). The molecular weight was 554.
The fraction 4140-5100 ml yielded 250 mg of a compound (B) with purity 99.0%. Melting point: 250-55C. [~]25 = +28.5 (c=0.246; CH2C12). The molecular weight was 554. The methine signal from the ester group is shifted 0.13 ppm downfield in lH-NMR spectrum of B compared to A, while the rest of the spectra are nearly identical. The electron impact mass spectra of A and B are identical apart from the intensities of the mass peaks. These spectroscopic differences and similarities indicate that A
and B are epimers due to the chiral centre in the ester group.
B. 6~,9~-Difluoro-ll~-hydroxy-16~,17~- ~(l-methylethylidene)bis(oxy)~
androsta-1,4-diene-3-one-17~-carboxylic acid (200 mg) was dissolved in 25 ml of dimethylformamide. l-Chloroethyl ethyl carbonate (100 mg), potassium hydrogen carbonate (70 mg) and 18-crown-6-ether were added.
The reaction mixture was stirred at 80C for 3 h, cooled, extracted with methylene chloride after addition of 150 ml of water, dried and evaporated. The crude product was purified in the same way as in procedure A leaving 207 mg of l'-ethoxycarbonyloxyethyl 6,9~-difluoro--11~-hydroxy-16c~17~- ~(l-methylethylidene)bis(oxy)~ androsta-l,4-diene--3-one-17B-carboxylate. The purity (HPLC) was 98.4% and the ratio epimer A/B, 54/46.
C. 6~ 9-Difluoro-ll~-hydroxy-16~ 17~- ~l-methylethylidene)bis(oxy)~
androsta-1,4-diene-3-one-17~-carboxylic acid (200 mg) and 1,5-diazabicyclo [5.4.0] und~cene-5 (140 mg) were suspended in 25 ml of benzene and warmed to reflux. A solution of l-bromoethyl ethyl carbonate (175 mg) in 5 ml of benzene was added and the mixture was refluxed for 2 1/2 h. After cooling 50 ml of methylene chloride was added and the solution was washed with water, dried and evaporated. The crude product was purified in the same way as in procedure A, yielding 207 mg of 1'--ethoxycarbonyloxyethyl 6~ 9a-difluoro-llB-hydroxy-16~,17~-~- [(l-methyl-ethylidene)bis(oxy)~ androsta-1,4-diene-3-one-17~-carboxylate. The purity (HPLC) was 96.4% and the ratio epimer A/B, 44/56.
D. To a solution of 6~,9~-difluoro-llB-hydroxy-16~,17~- [(l-methylethyl-idene)bis(oxy)~ androsta-1,4-diene-3-one-17B-carboxylic acid (100 mg) in 25 ml of acetone 175 mg of ~-bromodiethylcarbonate and 45 mg of anhydrous potassium carbonate were added. The mixture was heated for 6 h at reflux. The cooled reaction mixture was poured into 150 ml of water and extracted with methylene chloride. The extract was washed with water, dried over sodium sulphate and evaporated yielding 65 mg of solid _ J
l'-ethoxycarbonyloxyethyl 6~,9a-difluoro-llB-hydroxy-16~ 17~, ~(l-methylethylidene)bis(oxy)~ androsta-1,4-diene-3-one-17B-carboxylate.
The purity determined by HPLC was 97.6% and the ratlo epimer A/B, 49/51.
E. 6~,9~-Difluoro-ll~-hydroxy-16~,17~- ~(l-methylethylidene)bis(oxy)~
androsta-1,4-diene-3-one-17B-carboxylic acid (500 mg) and tetrabutylammonium hydrogen sulphate (577 mg) were added to 3 ml of lM
sodium hydroxide.A solution of 435 mg of l-bromoethyl ethyl carbonate in 50 ml of methylene chloride was added. The mixture was refluxed with stirring overnight. The two layers were separated. The organic layer was washed with 2xlO ml of water, dried and evaporated. The crude product was purified by chromatography on a Sephadex LH-20 column (72x6.3 cm) using chloroform as mobile phase. The fraction 1545-1950 ml was collected and evaporated and the residue precipitated from methylene chloride - petroleum ether leaving 341 mg of l'-ethoxycarbonyl-oxyethyl 6~,9~-difluoro-llB-hydroxy-16~,17d- ¦(l-methylethylidene)--bis(oxy)~ androsta-1,4-diene-3-one-17B-carboxylate. The purity determined with HPLC was 99.2% and the ratio epimer A/B, 56/44.
F. 6~,9~-Difluoro-llB-hydroxy-16~,17- ~(l-methylethylidene)bis--(oxy)~ androsta-1,4-diene-3-one-17~-carboxylic acid (200 mg) and tricaprylmethylammonium chloride (200 mg) were added to 5 ml of saturated aqueous NaHC03. A solution of 100 mg of l-bromoethyl ethyl carbonate in 10 ml of methylene chloride was added. The mixture was stirred at 45C for 20 h, diluted with 10 ml of methylene chloride and isolated and purified in the same way as in procedure E yielding 254 mg of l'-ethoxycarbonyloxyethyl 6C~-difluoro-llB-hydroxy--16~17~- r( l-methylethylidene)bis(oxy)~ - androsta-l,4-diene-3-one--17~-carboxylate. The purity (HPLC) was 97.4% and the ratio epimer A/B, 60/40.
G. 6C~9~-Difluoro-llB-hydroxy-16~,17~- ~(l-methylethylidene)bis(oxy)~
androsta-1,4-diene-3-one-17B-carboxylic acid (200 mg), l-bromoethyl ethyl carbonate (135 mg) and triethylamine (275 mg) were dissolved in 20 ml of dimethylformamide. The mixture was stirred at 80C for 3 h, diluted with 200 ml of methylene chloride, washed with water, dried and evaporated. The crude product was purified in the same way as in 18 133~845 procedure A yielding 69 mg of l'-ethoxycarbonyloxyethyl 6~,9~-difluoro-~ -hydroxy-16~,17~- r(l-methylethylidene)bis(oxy)l androsta-1,4--diene-3-one-17B-carboxylate. The purity (HPLC) was 97.8% and the ratio epimer A/8, 48/52.
Exempel S. l'-Acetoxyethyl 6~,9~-difluoro-llB-hydroxy-16~,17~-~(l-methylethylidene)bis(oxy)] androsta-1,4-diene-3-one-17B-carboxylate.
6~,9~-Oifluoro-llB-hydroxy-16O~17~- [(l-methylethylidene)bis(oxy)) androsta-1,4-diene-3-one-17B-carboxylic acid (500 mg) and potassium hydrogen carbonate (575 mg) were dissolved in 40 ml of dimethylformamide. l-chloroethyl acetate (1 ml) was added and the reaction mixture was stirred at room temperature for 40 h. The reaction mixture was poured ;nto 50 ml of water and extracted with methylene lS chloride. The extract was washed with aqueous sodium hydrogen carbonate and water, dried and evaporated. The residue was chromatographed on Sephadex LH-20 column (72x6.3 cm) using chloroform as mobile phase. The fractions 1755-2025 and 2026-2325 ml were collected and evaporated.
The solid product from fraction 1755-2025 ml was further purified by chromatography on a sephadex LH-20 column (76x6.3 cm i.d.) using a mixture of heptane-chloroform-ethanol, 20:20:1, as mobile phase. The fraction 2505-2880 ml was collected and evaporated. the residue was dissolved in methylene chloride and precipitated with petroleum ether leaving 167 mg of solid product (A). The purity determind by HPLC was 99.1%. Melting point 238-59C. !~u~2~5 = +94 (c=0.192; CH2C12). The molecular weight was 524.
The solid product from fraction 2026-2325 ml above was further purified by chromatography in the same way as above. The fraction 5100-5670 ml was collected and evaporated. The residue was dissolved in methylene chloride and precipitated with petroleum ether yielding 165 mg of solid product (8). The purity determined with HPLC was 99.4%. Melting point 261-65C. ~]D5 = +34 tc=0.262; CH2C12). The molecular weight was 524.
The lH-NMR spectra of A and B are nearly identical with the exception of the methine quartet from the ester group which is shifted 0.16 ppm downfield in compound B compared to A. The fragmentation patterns of A
and B in electron impact mass spectra are identical apart from the intensities of the mass peaks. These spectroscopic properties of A and B
indicate that they are epimers due to the chiral centre in the ester group.
Exemple 6-88. The substance given in Table 1-3 below were prepared, isolated and purified in a manner analogous to that described in Examples 4 and 5.
13348~5 ,, ~, -- -- -- _ _ ~ ~o u~ o In U~ o ~ n co o \ / a) ~ In ~ u~ u~ O n o u~
m ~ ~ ~ ~ O co ~ ~
oo o~ ~ ~ o o ~r ~ oo ~ ~D
~ ~ ~ a) o 8~ ~ 3 ~' C3 ,~,\
) \
~) ~ o o ~r ~ ~o oo ~ --mr' ~ N~ ~ O 'J~, ~ ~ ~ r U~ 1- 0 /\
~D 00 ~ ~ I I ~ ~ ~u ~ a) o ~--8~ ~ ~ N ~ ~ 00 N 0 ~C~ N N N N N ~I
p, ~ m ~ m ~ m ~ m ~o ;_ _ ~ ~ ~ ~ ~ ~ ~ ~ ~) U
X ~ ~C :C -- --U U
/ \
~o o o '`' o= I I _ _ >~- -x ~ - - X
O ~ X
~h `~ ~
a) ~ ~ O o ~ c~
o X
` - 21 133~845 ~ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ c E u-) ~n o o o o m o o o O -- N r~ C~l O O 1~ U'~ O O Lr) O ~D IS) O 0 0 C~ 0 c E
U~ o U~ o U~ o U~ o o U~ o~ o U~ o c ~
D OD ~ ~ O O O O C~ 00 0 C~ 0 ~D ~D O O
-_ _~ ~D 0~ ~ ~ O O O O ~ C~ o o o O 0CO C~ 0 ISI U~ _ r U C~J
~ _ OOOOOOOOOOOOOOOOOO
D 01 ) _ 00 0 O- 0 ~1 _ ~D 0 O~ u~ _ Ir) o ~ o ~5 o ~ cn ~ D cn ~ o u~ o ~ o c~ ~ a ~ 0 ~
T + + + + + _ + _ + _ + + + + + + + +
O1~ N 1~ ~ ~ ~ t~ _ O a~ 1~ _ O
o I I I I O
~a) o d- O O ~ In u~ d 1~ Il~ O C~
S ~J~J _ _ ~ 1 C~l C~J ~J N C~
L
a~
E c~
_ ct: m I cC m ~ n cc m ~ cc m ~: m ~ m ~)OOOOOOOOOOOOOOO
~r) I
tY I I C) V <--~ ~ V ~_) o c) ~ ~ ~ ~ I I I ~ I I :C
C C~l o -- a .
a) ~ d~ 1~) D r~ a~ O _ N ~) ~ Ir') ~9 1~ 00 Cl~ O
~ ,a C~ .
- J
-- . 22 1334845 C E O ~ O O
O ~ O O O~ ~ ~ O
_ o a~
o U~ o U~ U~ o U~
O ~ I~ O ~ S
aJ O C~ 0 0 ~
a,., _ D
_ O
v~ c D E
a1 o ao co oo a~ o E
~ _ ~ . .
_ O
O ..
N C~J C~ D 00 ~ O
O
N
aJ
O
c C . , o ._ ~ C --~ ~ S S
N O ~1 _ o o o o o o Sa)C~
O ~ O 00 0 ~ t O N ~D O ~1 T + _ + + + + ~ C _ _D
+ ~ ~ ~ ~O
c ~ D DE
~ o o c~ s a s E ~ ~E
o o 1~ o o~ x ~0 E ~ E E O
" _ _ _ ~J N C`J O O O O
O O O O
~ ~ t ~_ ~ O ~ O O
E m cr~
_ + ~: a~ + ~ a: I s s ~r cc u o c ~ ~ c v ._ ~.. . ~
v~ v)v~
E E
t~ ~ ~ E E E
. .
^ ^ -- ~ ~ ~ ~ ~ X ~ ~ X
tr I I I ~ O O~_ X ~ X X
T I T -r O O O O O O O
E E E EE
~ ~ ~ ~ ~3 U~ T _ _ _ __ tY I I I T I I ~ O OO O O
O O O O O
N N N N N
T
J J J J J
X X X X
~ _ S ~ ~ S
C CL ~ C~
~ N ~O ~ a1 aJ tlJ
c o C C C C C
X LL L~ LL LL L~ ~ ~
--E~ ) ~) ~ ~ ~) _ N ~ ~ u~
~ ~O
1334~45 E ~r) o o o ~
o ~ o ~ o ~ o U~ ~ I~
~ J - E
o- o U ~ o o U~ o O
~ ~ _ ~ -- ~ 0 0 ~ C~J _ / \ ~ O ~1 _ N ~ C~ L~
O O
i I ~
O E _ ~ N Ot) O 00 ~0 ~D N O 0 I t J -- ~ ~U O O ~ ~ ~t d ~ ~ u~ ~o o 1/ ~
\
0 C~ ~D ~ ~ O 0~
O ~ 0 0 ~ eJ ~ ~ ~ U~ D
. o o O O O C- ~:
11 S + + + + + + +
.0 ~
00 Lt') O ~_ E E
O O ~ o~ l L ~ ~ L~ D oO v~
~ a~ ~ o L~) ~) 00 0 O~ E ~ ~ L ~ ~ L~ D t~ ~ ~ o ~ 'Q O
v ~( E cn a~ L
) \ v) cn V~
E E
~ ~ ~ ~ ~ ~ ~ ~ ~ Ln ID -- -- -- ~ ~) I
IY I t~ ~ O I I ~r~J 1~ 1~1 X X
) O O O O O _ _ O= _ ~) ~ ~ ~ ~ ~ ~) ~
~ I I I I I I I I I I o o CY~J~I I ~_) O ~ O O ~ O O N N
O ~ /-- N C~l N N N N N N
V ~ N N N N N N N N J
~) I I I I I I I I
n-S~_-- X X I I I I I I I I 1 O I r ~ X I ~ 1~ c C
\ \ O O
N ~ ~ - C) aJ \~ Q a~ O _ N ~ ~ L
24 1 133~5 _ _ ~ _ _ _ _ ~ ~ _ _ ~ E u~ o o o u~ o o n -- O -- ~ ~O O 1~ 1~ ~ O U~ O C~l E , ~ N ~J N ~ ~
j ~ o ~n o u- u~ O O O O o O u~ ~ O O ~ ~ O ~n ~, ~ ~ C`J ~ a:~ o o o o c~ oo ~ _ ~ O O O ~ ';t N C~J ~J t~J
C~ 3 ~ / r--/\ ~
N C~ CO O O 0 0 0 ) 00 O 1~1 0 0 ~ d- ~J NC~J N ~:t Ct ~t O '~ I E
O
O
\ U~ C~J
I _ o o o o o o o o o o O C~ D O ~) O d -- d-11 I + + + + _ + _ + _ +
~ ~ + + +
O
N ~0 _ u~ ~D N ~ r) O
S _ _ ~ J ~I N-- N _ N
N _ L
E I I I I ~t: m ~ a~
oo Y I I ' ~D ~ ~ ~ ~
Q!~ -~ e ~ ~ ~ ~ ~ I~) I I I I I
Y I T I I T
I T
I T I I --~ ~ I I I I I
O O C~
o '~ I CY I ~ I I I I I I I I
o u~
V
I t~ _ -- I N
\ ~! ~
~-- X~ X~
O I \ ~ X
a ~ O E ~
_ n~ o ~ n 1,~34845 _ _ _ _ ~ ~r ~ _ N N N N N ~I N N N U') C E Ou~ o o -- o1~ ~ oou ~ o o1~ o o u o- o ~ ~ O O
.~ ~C~J ~ _ N N~) N t~ ~t ~ ~D ~ u ~ ID U~
c E '' ' ' l l l ' ' ' oo o o oU~ o o U~
_ O ~D O N n ~ N ~ O O O 0 ~ ~
al o _ 1~ 1~ JC~J ~ N ~) et ~ u~ ~ ~ C) ~ ~ N
C~ ~ N N _ -- N
C ~
cn c ~ ~ N C~ N N O O 00 ~ ~ ~ OD
--a~ u N N '~ ~ ~ CO N N O O C:) 0 el~ ~ 00 0 s U u~
U~ ._ _ O C~J
~ In u~ r~ cn ~o ' o O a~
O C~J 1~ 1~ 1-- D tO 1~ 'J- 1~ O ~ _ 1~) 0~ N O 1'~ 0 Il I + + + + + + + + _ + _ + + + _ + _ +
U ~ + + + +
-cr.
O N C~ O C~ 00 'J u~
U~ 1~ O O _ _ ~ ~D ~0 00 '~ N ~t _ _ '.~J 00 N _ -- _ -- _ N _ _ _ -- N _ _ N N
L
a~
E m m ~ m, I I I I I + + ~: m ~ m c~: m ~: m cr N N N
~O I I -- -- -- -- I T 5 1 ~ :r -- -- I I -- --O O O O O O O O O O O O O O O O
I T I I I I T I I I I I .I
S
N N N N N N N N N N N N ~`J
N ^ ^ ^ ~ _ ~ ~ ~ _ _ _ ~ _ ~Y N N I ~`J I N C~l C`J I C~l ~`J C~l I I N C~J N C~J
T
_ I
N N C~l N C~l ~! I I -- I -- I I I -- I I I -- -- I I I I
-- N N N N N
~ I I I I I
~ _ _ _ _ ~
c ._ N
X I I T I I I 1~_ 1~ I I I I I I I I I I
o ~ ~11 .
-- E . 0~ .-- N .. ~ ~ u~ oo ~ O _ N 1~ ~ n 26_~ 33~18~15 _ ~ N N N N Ir~ N
o -- o o -) o ~ U~ o ~n o u~ o o c E ' ' ' I ' I ' Oo ~ ~ Lr o U~ o o _ o o o _ CO ~ ~ ~" O ~D N ~ . el~
O ~In ~ ~ I t~ ~) 1~ N ~ ' _ _ ID
~r) . N N ~) ~ .
S ~
~_ ~ ~ ~ el- et 00 0 00 CO C~ N N N N
V~
............. _ ~COCO0~ NNNN
E
c ._ _ ~
N ~_ N~N~ 000000000000 r-~ON ~.~N~O~I _O
~III ++_++++_++++ ~N
~ ~ + + O ~-_ NO
O _ N~N_OO~_~N -r ~ N~N_~ O ~
o IIIIIIIIIIII Ca~aJs O~-~N~ O~Q
Q NNN~__~NI CS~
NNNN__ NN_NN ~SS~
I _ E G~
o E Ct~ a~ E ~ ~ -- E
o o o o V7 o o E r~l _ ~ (n ~n E
o ~ o ~ _ N N N -- ~) O
_ _ _ s , E E '--~O I I I I I I I I I I I I I I c ~ O
T 1. I I l I T ~ 1 Q _ _ S
OOOOOGOOOOOOO ~S__ SCl~
~ ~ _ I I I I I I I I I I I I O Cv1 c C ~
~ _ ~ ~ E
E E E Lr ~t I I I I I I I I I I I I I ~) N ~ U'~ X
X X X
~D 1~ N O
-- -- -- -- --__ NNNNNNN E E E E E
N II NNNNNNN
II~IIIIIIIII --___ _ ~ <_,~ ~) ~ ~ ~ ~ O O O O O
O O O O O
~NNNN
~ II IIIII
II NN
~IINN T IIIIII XXXXX
~ S S S S S
c Q~QQQ
_ N ~
X LL ~ L~ ~ LL ~ ~ ~ ~ ~ L- L~ ~ O Cl O O O
~ ~IJ
-- EQ ~o r~ oo ~ o _ ~
Example ~9 . Pharmaceutical Preparations The following non-limitative examples illustrate formulations intended for different topical forms of administration. The amount of active steroid in the percutaneous formulations are ordinarily 0.001-0.2% (w/w), preferably 0.01-0.1% (w/w).
Formulation 1, Ointment Steroid, micronized0.025 9 Liquid paraffin 10.0 9 White soft paraffinad 100.0 9 Formulation 2, Ointment Steroid 0.025 9 Propylene glycol 5.0 9 Sorbitan sesquioleate5.0 9 Liquid paraffin 10.0 9 White soft paraffinad 100.0 9 For,nulation 3, Oil in water cream Steroid 0.025 9 Cetanol 5.0 9 Glyceryl monostearate5.0 9 Liquid paraffin 10.0 9 Cetomacrogol 1000 2.0 9 Citric acid 0.1 9 Sodium citrate 0.2 9 Propylene glycol 35.0 9 Water ad 100.0 9 ~ 28 1334845 Formulation 4, Oil in water cream Steroid, micronized 0.025 9 White soft paraffin 15.0 9 Liquid paraffin 5.0 9 Cetanol 5.0 9 Sorbimacrogol stearate 2.0 9 Sorbitan monostearate 0.5 9 Sorbic acid 0.2 9 Citric acid 0.1 9 Sodium citrate 0.2 9 Water ad 100.0 9 Formulation 5, Water in oil cream Steroid 0.025 9 White soft paraffin35.0 9 Liquid paraffin 5.0 9 Sorbitan sesquioleate5.0 9 Sorbic acid 0.2 9 Citric acid 0.1 9 Sodium citrate 0.2 9 Water ~ ad 100.0 9 Formulation 6, Lotion Steroid 0.25 mg Isopropanol 0.5 ml Carboxyvinylpolymer 3 mg NaOH q.s.
Water ad 1.0 9 29 13348~5 Formulation 7, Suspension for injection Steroid, micronized 0.05-10 mg Sodium carboxymethylcellulose7 mg NaCI 7 mg Polyoxyethylene (20) sorbitan monoleate O.S mg Phenyl carbinol 8 mg Water, sterile ad 1.0 ml Formulation 8, Aerosol for oral and nasal inhalation Steroid, micronized 0.1 % w/w Sorbitan trioleate 0.7 % w/w Trichlorofluoromethane 24.8 % w/w Dichlorotetrafluoromethane24.8 % w/w Dichlorodifluoromethane49.6 % w/w Formulation 9, Solution for atomization Steroid 7.0 mg Propylene glycol 5.0 9 Water ad 10.0 9 Formulation 10, Powder for inhalation A gelatin capsule is filled with a mixture of Steroid, micronized 0.1 mg Lactose 20 mg 0 The powder is inhaled by means of an inhalation device.
Pharmacology _ The affinity of the new androstane-17~-carboxylic acid esters to the glucocorticoid receptor All steroids according to the present invention are physiologically active compounds. The affinity of the novel androstane-17B-carboxylic acid esters to the glucocorticoid receptor has been used as a model for determination of the anti-inflammatory potency. Their receptor affi-nities have been compared to budesonide ~[22R,S]-16~,17~-butylidenedioxy-llB,21-dihydroxypregna-1,4-diene-3,20-dione) a highly active glucocorti-coid with a favourable ratio between local and systemic effects (Thalén and Brattsand, Arzneim.-Forsch. 29, 1687-90 (1979)).
Male Sprague-Dawley rats, one to two months of age, were used throughout the investigation. The thymus was removed and put into ice-cold saline.
The tissue was homogenized in a Potter Elvehjem homogenizer in 10 ml of a buffer containing 20 mM Tris, pH 7.4, 10 % (w/v) glycerol, 1 mM
EDTA, 20 mM NaMoO4, 10 mM mercaptoethanol. The homogenate was centri-fuged for 15 min at 20,000 x 9. Portions of the 20,000 x 9 supernatant (230 ~1) were incubated for abowt 24 h at 0C with lOC ~1 phenylmethyl-sulphonylfluoride (an esterase inhibitor, final conc. 0.5 mM), 20 ~1 unlabelled competitor and 50 ~1 3H-labelled dexamethasone (final conc.
3 nM). Bound and free steroid were separated by incubating the mixture with 60 ~1 2.5 % (w/v) charcoal and 0.25 % (w/v) dextran T70 suspension in 20 mM Tris, pH 7.4, 1 mM EDTA, and 20 mM NaMoO4 for 10 min at 0C.
Following a centrifugation at 500 x 9 for 10 min, 230 ~1 of the super-natant was counted in 10 ml Insta-Gel in a Packard scintillation spectro-photometer. The supernatants were incubated with a) [3H]dexamethasone alone, b) [3H]dexamethasone plus 1000 fold excess of unlabelled dexa-methasone and c) [3H]dexamethasone plus 0.03-300 fold "excess" of compe-titor. The nonspecific binding was determined when 1000 fold excess of unlabelled dexamethasone was added to [3H]-labelled dexamethasone.
The radioactivity bound to the receptor in the presence of competitor divided by the radioactivity bound to the receptor in the absence of competitor multiplied by 100 gives the percentage specific binding of labelled dexamethasone. For each concentration of a competitor the per-133~845 . 31 centage specifically bound radioactivity is plotted against the log of concentration of competitor. The curves are compared at the 50 %
specific binding level and referenced to budesonide, which is assigned a relative binding affinity (RBA) of 1.
Table 4. Table summarizing relative binding affinities (RBA) to the glucocorticoid receptor of some of the investigated compounds.
Compound according RBA
to Ex. No.
Budesonide . 4 epimer B 0.30 5 epimer B 0.17 27 0.50 3~ 0.04 0.20 64 0.05 69 0.44 84 1.03 87 0.63
Claims (10)
1. A process for the preparation of a compound of the formula or a stereoisomeric compound thereof, in which formula the 1,2-position is saturated or is a double bond, X1 is selected from hydrogen, fluorine, chlorine and bromine, X2 is selected from hydrogen, fluorine, chlorine and bromine, R2 is selected from straight and branched hydrocarbon chains having 1 to 10 carbon atoms and R7 is hydrogen or an acyl group with 1 to 10 carbon atoms arranged in a straight or branched chain, characterized by reaction of a steroid compound of the formula with an aldehyde compound of the formula wherein X1, X2, R2, R7 and ? have the meanings given above, in the presence of perchloric acid.
2. A process according to claim 1 wherein X1 and X2 are both selected from hydrogen and fluorine.
3. A process according to claim 1 wherein there is a double bond at the 1,2-position of the steroid compound.
4. A process according to claim 1, 2 or 3 wherein the compound of formula is acetaldehyde, propanal, butanal, isobutanal, pentanal, 3-methylbutanal, 2,2-dimethylpropanal, hexanal, heptanal, octanal, nonanal or dodecanal.
5. A process according to claim 1, 2 or 3 wherein the steroid is added to a solution of the aldehyde together with perchloric acid as catalyst in an ether, a halogenated hydro-carbon, an aromatic hydrocarbon, an alicyclic hydrocarbon or an aliphatic hydrocarbon.
6. A process according to claim 1 wherein in the formula there is a double bond at the 1,2-position and R7 is hydrogen.
7. A process according to claim 1 wherein in the formula there is a single bond at the 1,2-position and R7 is hydrogen.
8. A process according to claim 6 wherein X1 and X2 are both fluorine.
9. A process according to claim 7 wherein X1 and X2 are both fluorine.
10. A process according to claim 6, 7 or 8 wherein the aldehyde compound is n-butyraldehyde.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000589467A CA1334845C (en) | 1985-04-04 | 1989-01-27 | 16,17-acetalsubstituted androstane-17.beta.-carboxylic acid esters |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8501693-9 | 1985-04-04 | ||
| SE8501693A SE8501693D0 (en) | 1985-04-04 | 1985-04-04 | NOVEL 16,17-ACETALSUBSTITUTED ANDROSTANE-17BETA-CARBOXYLIC ACID ESTERS |
| CA000505744A CA1333597C (en) | 1985-04-04 | 1986-04-03 | 16,17-acetalsubstituted androstane-17.beta.-carboxylic acid esters |
| CA000589467A CA1334845C (en) | 1985-04-04 | 1989-01-27 | 16,17-acetalsubstituted androstane-17.beta.-carboxylic acid esters |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000505744A Division CA1333597C (en) | 1985-04-04 | 1986-04-03 | 16,17-acetalsubstituted androstane-17.beta.-carboxylic acid esters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1334845C true CA1334845C (en) | 1995-03-21 |
Family
ID=25670953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000589467A Expired - Lifetime CA1334845C (en) | 1985-04-04 | 1989-01-27 | 16,17-acetalsubstituted androstane-17.beta.-carboxylic acid esters |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1334845C (en) |
-
1989
- 1989-01-27 CA CA000589467A patent/CA1334845C/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5939409A (en) | Processes for the production of anti-inflammatory steroids | |
| EP0054010B1 (en) | 4-pregnene-derivatives, a process for their preparation and composition for the treatment of inflammatory conditions | |
| GB2247680A (en) | Acetals and esters of 16alpha-hydroxyprednisolone and fluocinolone | |
| EP0143764B1 (en) | Novel androstane-17 beta-carboxylic acid esters, a process and intermediates for their preparation, composition and method for the treatment of inflammatory conditions | |
| CA1333597C (en) | 16,17-acetalsubstituted androstane-17.beta.-carboxylic acid esters | |
| IE58309B1 (en) | Novel androstane-17 beta-carboxylic acid esters | |
| CA1334845C (en) | 16,17-acetalsubstituted androstane-17.beta.-carboxylic acid esters | |
| EP0232690B1 (en) | Novel 16,17-acetalsubstituted pregnane-21-oic acid derivatives, process for the preparation thereof and pharmaceutical preparation containing them | |
| IE66261B1 (en) | Preparation of intermediates for 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters | |
| US5215979A (en) | 16,17-acetalsubstituted pregnane 21-oic acid derivatives | |
| Hong et al. | Synthesis of 6-(methoxycarbonyl) prednisolone and its derivatives as new antiinflammatory steroidal antedrugs | |
| NZ230570A (en) | The preparation of intermediate 16,17-acetal substituted androstang-17#b#-carboxylic acid esters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |